UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

for the quarterly period ended June 30, 2007

OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

for the transition period from ________ to _________
Commission file number 1-10638

CAMBREX CORPORATION
(Exact name of registrant as specified in its charter)

         DELAWARE                                 22-2476135
         --------                                 ----------
(State or other jurisdiction of                 (I.R.S. Employer
incorporation or organization)                Identification No.)

ONE MEADOWLANDS PLAZA, EAST RUTHERFORD, NEW JERSEY 07073
(Address of principal executive offices)

(201) 804-3000
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes [X]. No [ ].

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer"in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer [ ] Accelerated filer [X] Non-accelerated filer [ ]

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [ ]. No [X].

As of July 31, 2007, there were 28,889,915 shares outstanding of the registrant's Common Stock, $.10 par value.


CAMBREX CORPORATION AND SUBSIDIARIES

FORM 10-Q

For The Quarter Ended June 30, 2007
Table of Contents

                                                                                                                  Page No.
                                                                                                                  --------
Part I Financial information

        Item 1.  Financial Statements

                 Consolidated Balance Sheets as of June 30, 2007 and December 31, 2006                                   2

                 Consolidated Statements of Operations for the three and six months ended June 30, 2007 and 2006         3

                 Consolidated Statements of Cash Flows for the six months ended June 30, 2007 and 2006                   4

                 Notes to Unaudited Consolidated Financial Statements                                               5 - 22

        Item 2.  Management's Discussion and Analysis of Financial Condition and Results of Operations             23 - 28

        Item 3.  Quantitative and Qualitative Disclosures about Market Risk                                             29

        Item 4.  Controls and Procedures                                                                                29

Part II Other information

        Item 1.  Legal Proceedings                                                                                      30

        Item 1A. Risk Factors                                                                                           30

        Item 6.  Exhibits                                                                                               30

Signatures                                                                                                              31


Part I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CAMBREX CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except share data)

                                                                            JUNE 30,    DECEMBER 31,
                                                                             2007          2006
                                                                          -----------   ------------
                                                                          (UNAUDITED)
ASSETS
Current assets:
   Cash and cash equivalents                                              $    41,233   $     33,746
   Trade receivables, net                                                      29,959         38,552
   Inventories, net                                                            60,125         53,893
   Assets of discontinued operations                                               --         79,383
   Prepaid expenses and other current assets                                   19,306         19,176
                                                                          -----------   ------------
        Total current assets                                                  150,623        224,750

Property, plant and equipment, net                                            145,425        141,863
Goodwill                                                                       33,219         32,573
Assets of discontinued operations                                                  --        202,292
Other non-current assets                                                        7,368          4,898
                                                                          -----------   ------------

        Total assets                                                      $   336,635   $    606,376
                                                                          ===========   ============

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
   Accounts payable                                                       $    22,048   $     28,592
   Accrued expense and other current liabilities                               70,780         45,141
   Liabilities of discontinued operations                                          --         33,401
                                                                          -----------   ------------
        Total current liabilities                                              92,828        107,134

Long-term debt                                                                 85,700        158,600
Deferred income tax                                                            21,374         14,268
Liabilities of discontinued operations                                             --         24,208
Accrued pension and postretirement benefits                                    38,863         39,911
Other non-current liabilities                                                  18,515         15,609
                                                                          -----------   ------------
        Total liabilities                                                     257,280        359,730

Stockholders' equity:
   Common stock, $.10 par value; authorized 100,000,000, issued
     31,257,445 and 30,145,319 shares at respective dates                       3,125          3,015
   Additional paid-in capital                                                  96,611        241,360
   Retained earnings                                                            2,274         28,860
   Treasury stock, at cost, 2,391,330 and 2,446,097 shares at respective
   dates                                                                      (20,365)       (20,832)
   Accumulated other comprehensive loss                                        (2,290)        (5,757)
                                                                          -----------   ------------

        Total stockholders' equity                                             79,355        246,646
                                                                          -----------   ------------
        Total liabilities and stockholders' equity                        $   336,635   $    606,376
                                                                          ===========   ============

See accompanying notes to unaudited consolidated financial statements.

2

CAMBREX CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

(in thousands, except per-share data)

                                                           THREE MONTHS ENDED            SIX MONTHS ENDED
                                                                JUNE 30,                     JUNE 30,
                                                         -----------------------   --------------------------
                                                            2007         2006          2007          2006
                                                         ----------   ----------   ------------   -----------
Gross sales                                              $   63,081   $   63,031   $    128,078   $   117,151
     Allowances and rebates                                     184          284            774           670
                                                         ----------   ----------   ------------   -----------
Net sales                                                    62,897       62,747        127,304       116,481

     Other revenues                                             (42)        (405)           765        (1,052)
                                                         ----------   ----------   ------------   -----------
Net revenues                                                 62,855       62,342        128,069       115,429

Cost of goods sold                                           38,917       39,902         79,736        73,904
                                                         ----------   ----------   ------------   -----------
Gross profit                                                 23,938       22,440         48,333        41,525

Operating expenses:
     Selling, general and administrative expenses            10,556       14,998         25,903        27,488
     Research and development expenses                        2,961        3,077          5,561         5,439
     Restructuring expenses                                   1,901           --          3,583            --
     Strategic alternative costs                              4,564        1,042         27,694         2,030
                                                         ----------   ----------   ------------   -----------
        Total operating expenses                             19,982       19,117         62,741        34,957

Operating profit/(loss)                                       3,956        3,323        (14,408)        6,568
Other (income)/expenses:
     Interest (income)/expense, net                            (871)         122         (2,410)        5,566
     Other expenses, net                                        401          125            382           130
                                                         ----------   ----------   ------------   -----------
Income/(loss) before income taxes                             4,426        3,076        (12,380)          872

     Provision/(benefit) for income taxes                     1,971        3,424           (392)        5,924
                                                         ----------   ----------   ------------   -----------
Income/(loss) from continuing operations                 $    2,455   $     (348)  $    (11,988)  $    (5,052)

(Loss)/income from discontinued operations, net of tax         (181)       1,324        219,478         4,851
                                                         ----------   ----------   ------------   -----------
Income/(loss) before cumulative effect of a change in
accounting principle                                          2,274          976        207,490          (201)

Cumulative effect of a change in accounting principle            --           --             --          (228)
                                                         ----------   ----------   ------------   -----------
Net income/(loss)                                        $    2,274   $      976   $    207,490   $      (429)
                                                         ==========   ==========   ============   ===========

Basic earnings per share:
     Income/(loss) from continuing operations            $     0.09   $    (0.01)  $      (0.42)  $     (0.19)
     (Loss)/income from discontinued operations, net of
     tax                                                 $    (0.01)  $     0.05   $       7.73   $      0.18
     Cumulative effect of a change in accounting
     principle                                           $       --   $       --   $         --   $     (0.01)
                                                         ----------   ----------   ------------   -----------
     Net income/(loss)                                   $     0.08   $     0.04   $       7.31   $     (0.02)

Diluted earnings per share:
     Income/(loss) from continuing operations            $     0.08   $    (0.01)  $      (0.42)  $     (0.19)
     Income from discontinued operations, net of tax     $     0.00   $     0.05   $       7.73   $      0.18
     Cumulative effect of a change in accounting
     principle                                           $       --   $       --   $         --   $     (0.01)
                                                         ----------   ----------   ------------   -----------
     Net income/(loss)                                   $     0.08   $     0.04   $       7.31   $     (0.02)

Weighted average shares outstanding:
     Basic                                                   28,711       26,741         28,393        26,701
     Effect of dilutive stock based compensation                238           --             --            --
                                                         ----------   ----------   ------------   -----------
     Diluted                                                 28,949       26,741         28,393        26,701

     Cash dividends paid per share                       $    14.00   $     0.03   $      14.03   $      0.06
                                                         ==========   ==========   ============   ===========

See accompanying notes to unaudited consolidated financial statements.

3

CAMBREX CORPORATION AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(unaudited)

(in thousands)

                                                                  SIX MONTHS ENDED
                                                                      JUNE 30,
                                                              ---------------------------
                                                                   2007           2006
                                                              ------------   ------------
Cash flows from operating activities:
   Net income/(loss)                                          $    207,490   $       (429)
   Adjustments to reconcile net income/(loss) to cash flows:
   Cumulative effect of a change in accounting principle                --            228
   Depreciation and amortization                                     9,645          9,633
   Write-off of debt origination fees                                  841            463
   Strategic alternative and restructuring charges                  21,862             --
   Stock based compensation included in net income/(loss)            4,589            808
   Deferred income tax provision                                     6,991          (469)
   Inventory reserve                                                 2,165            942
   Other                                                               206            246
   Changes in assets and liabilities:
     Receivables                                                     9,041          2,162
     Inventories                                                    (7,807)       (10,081)
     Prepaid expenses and other current assets                         692           (800)
     Accounts payable and other current liabilities                 (9,961)         4,063
     Other non-current assets and liabilities                         (599)           171
   Discontinued operations:
     Gain on sale of businesses                                   (235,607)            --
     Rutherford settlement, net of tax                               4,007             --
     Changes in operating assets and liabilities                    (5,310)       (13,588)
     Other non-cash charges                                          1,359         10,639
                                                              ------------   ------------
   Net cash provided by operating activities                         9,604          3,988
                                                              ------------   ------------

Cash flows from investing activities:
   Capital expenditures                                            (11,774)        (9,638)
   Other investing activities                                          (15)            --
   Discontinued operations:
     Capital expenditures                                             (530)        (7,995)
     Proceeds from sale of business                                463,914             --
     Acquired in-process research and development                       --         (1,392)
     Other investing activities                                         11            (65)
                                                              ------------   ------------
   Net cash provided by/(used) in investing activities             451,606        (19,090)
                                                              ------------   ------------

Cash flows from financing activities:
   Dividends                                                      (402,200)        (1,604)
   Net (decrease)/increase in short-term debt                         (135)           246
   Long-term debt activity (including current portion):
     Borrowings                                                    127,200        176,000
     Repayments                                                   (200,222)      (177,975)
   Proceeds from stock options exercised                            20,947          1,267
   Other financing activities                                          (59)          (113)
   Discontinued operations:
     Debt borrowings                                                    --             14
     Debt repayments                                                  (254)          (748)
                                                              ------------   ------------
     Net cash used in financing activities                        (454,723)        (2,913)
                                                              ------------   ------------
Effect of exchange rate changes on cash and cash equivalents         1,000          2,320
                                                              ------------   ------------
Net increase/(decrease) in cash and cash equivalents                 7,487        (15,695)
Cash and cash equivalents at beginning of period                    33,746         45,342
                                                              ------------   ------------
Cash and cash equivalents at end of period                    $     41,233   $     29,647
                                                              ============   ============

See accompanying notes to unaudited consolidated financial statements.

4

CAMBREX CORPORATION AND SUBSIDIARIES

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS
(dollars in thousands, except share data)

(1) BASIS OF PRESENTATION

Unless otherwise indicated by the context, "Cambrex" or the "Company" means Cambrex Corporation and subsidiaries.

The accompanying unaudited consolidated financial statements have been prepared from the records of the Company. In the opinion of management, the financial statements include all adjustments, which are of a normal and recurring nature, except as otherwise described herein, and are necessary for a fair statement of financial position and results of operations in conformity with generally accepted accounting principles. These interim financial statements should be read in conjunction with the financial statements for the year ended December 31, 2006.

The results of operations for the three and six months ended June 30, 2007 are not necessarily indicative of the results to be expected for the full year.

Certain reclassifications have been made to prior year amounts to conform to the current year presentation.

In October 2006, the Company sold two businesses within the Human Health segment for nominal consideration. As a result of this transaction, the Company reported a non-cash charge of $23,244 in the fourth quarter of 2006, and all periods presented reflect the results of these businesses as discontinued operations.

In February 2007, the Company completed the sale of the businesses that comprised the Bioproducts and Biopharma segments (excluding certain liabilities) to Lonza Group AG for total cash consideration of $463,914, including working capital adjustments. As a result of this transaction, the Company reported a gain of $235,607, including working capital adjustments, and all periods presented reflect the results of these businesses as discontinued operations. Refer to Note 14 for a complete discussion on discontinued operations.

(2) IMPACT OF RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Accounting for Uncertainty in Income Taxes

The Company adopted Financial Accounting Standards Board ("FASB") Interpretation No. 48, Accounting for Uncertainty in Income Taxes -- an interpretation of FASB Statement No. 109 ("FIN 48") effective January 1, 2007. This interpretation clarified the accounting for uncertainty in income tax positions and required the Company to recognize in the consolidated financial statements the impact of a tax position that is more likely than not to be sustained upon examination based on the technical merits of the position. The effect of adopting this interpretation was not material. Refer to Note 5 for further discussion.

Accounting for Planned Major Maintenance Activities

The Company adopted FASB Staff Position ("FSP") No. AUG AIR-1 "Accounting for Planned Major Maintenance Activities" effective January 1, 2007. This FSP amended certain provisions of APB Opinion No. 28 "Interim Financial Reporting". This FSP prohibited the use of the accrue-in-advance method of accounting for planned major maintenance activities in annual and interim reporting periods. The adoption of this FSP had an immaterial impact on the Company's financial position and results of operations.

5

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(3) STOCK BASED COMPENSATION

Beginning January 1, 2006, the Company began recognizing compensation costs for stock option awards to employees based on their grant-date fair value. The value of each stock option is estimated on the date of grant using the Black-Scholes option-pricing model. The weighted-average fair value per share for the stock options granted to employees during the three and six months ended June 30, 2007 was $8.30. The weighted-average fair value per share for the stock options granted to employees during the three and six months ended June 30, 2006 was $7.73 and $8.02, respectively.

For the three months ended June 30, 2007 and 2006, the Company recorded $23 and $157, respectively, in selling, general and administrative expenses for stock options. In addition, the Company recorded $20 in restructuring expenses related to the reduction in workforce in the second quarter of 2007. For the six months ended June 30, 2007 and 2006, the Company recorded $96 and $158, respectively, in selling, general and administrative expenses for stock options. In addition, the Company recorded $198 and $37 in strategic alternative costs and restructuring expenses, respectively, for stock options related to the change in control agreements and the reduction in workforce in the first six months of 2007.

As of June 30, 2007, the total compensation cost related to unvested stock option awards granted to employees but not yet recognized was $685. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 2.4 years.

In addition, for the three and six months ended June 30, 2007, the Company recorded $2,417 in strategic alternative costs for expense associated with a stock option modification due to the special dividend paid on May 3, 2007. The modification reduced the exercise price of all stock options outstanding as of the dividend payment date by $14.00 per share, the amount of the special dividend. As of June 30, 2007, the total compensation cost related to unvested stock option awards that were modified but not yet recognized was $430. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 2.4 years.

Cambrex senior executives and certain employees participate in two long-term incentive plans which rewards achievement of long-term strategic goals with restricted stock units. For the three months ended June 30, 2007 and 2006, the Company recorded $92 and $227, respectively, in selling, general and administrative expenses for restricted stock. In addition, the Company recorded $140 and $65 in strategic alternative costs and restructuring expenses, respectively, in the second quarter of 2007. For the six months ended June 30, 2007 and 2006, the Company recorded $263 and $386, respectively, in selling, general and administrative expenses for restricted stock. In addition, the Company recorded $1,443 and $135 in strategic alternative costs and restructuring expenses, respectively, in the first six months of 2007, primarily for the acceleration of vesting related to restricted stock per the terms of the executive change in control agreements. As of June 30, 2007 the total compensation cost related to unvested restricted stock granted but not yet recognized was $1,221. The cost will be amortized on a straight-line basis over the remaining weighted-average vesting period of 1.6 years.

At June 30, 2006, the Company had outstanding 150,000 fully-vested cash-settled incentive SARs at a price of $19.30. These SARs were classified as liability awards and, as such, were recorded at fair value until the rights were exercised during the fourth quarter of 2006. As of June 30, 2007 the Company did not have any SARs outstanding. For the three and six months ended June 30, 2006 the Company recorded $46 and $264, respectively, in compensation expense. Under FAS 123(R), the Company is required to measure the SARs at fair market value. Prior to adopting FAS 123(R), the SARs were measured at the intrinsic value. In addition, during the first quarter of 2006, the Company recorded $228 in compensation expense as a cumulative effect of a change in accounting principle in accordance with FAS 123(R).

6

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(3) STOCK BASED COMPENSATION (CONTINUED)

The following table is a summary of the Company's stock option activity issued to employees and related information:

                                              WEIGHTED
                                              AVERAGE
                                 NUMBER OF    EXERCISE
          OPTIONS                 SHARES       PRICE
------------------------------  ----------   ---------
Outstanding at January 1, 2007   2,754,893   $   28.48
Granted                                 --          --
Exercised                         (792,221)  $   21.34
Forfeited or expired              (182,085)  $   23.55
                                 ---------
Outstanding at March 31, 2007    1,780,587   $   32.16
                                 ---------
Granted                             18,000   $   24.58
Exercised                         (324,305)  $   13.28
Forfeited or expired                (3,900)  $   12.90
                                 ---------
Outstanding at June 30, 2007     1,470,382   $   20.00
                                 =========
Exercisable at June 30, 2007     1,341,290   $   21.17

On May 3, 2007, the Company paid a special dividend of $14.00 per share. As a result, the market price of the stock declined by approximately $14.00 per share from the prior days close and therefore all outstanding options were modified to reduce the exercise price by $14.00 per share.

The aggregate intrinsic value for all stock options exercised during the three months ended June 30, 2007 and 2006 were $956 and $129, respectively. The aggregate intrinsic value for all stock options exercised during the first six months of 2007 and 2006 were $2,552 and $564, respectively. The aggregate intrinsic value for all stock options outstanding as of June 30, 2007 was $1,828. The aggregate intrinsic value for all stock options exercisable as of June 30, 2007 was $1,127.

A summary of the Company's nonvested stock options as of June 30, 2007 and changes during the three and six months ended June 30, 2007, are presented below:

                                             WEIGHTED-
                              NUMBER OF    AVERAGE GRANT-
  NONVESTED STOCK OPTIONS      SHARES     DATE FAIR VALUE
----------------------------  ---------   ---------------
Nonvested at January 1, 2007    236,952        $21.39
Granted                              --            --
Vested during period            (59,463)       $21.39
Forfeited                       (63,497)       $21.39
                                -------
Nonvested at March 31, 2007     113,992        $21.39
                                -------
Granted                          18,000        $24.58
Vested during period                 --            --
Forfeited                        (2,900)       $ 7.39
                                -------
Nonvested at June 30, 2007      129,092        $ 7.84
                                =======

7

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(3) STOCK-BASED COMPENSATION (CONTINUED)

A summary of the Company's nonvested restricted stock as of June 30, 2007 and changes during the three and six months ended June 30, 2007 are presented below:

                                            WEIGHTED-
                              NUMBER OF   AVERAGE GRANT-
 NONVESTED RESTRICTED STOCK    SHARES     DATE FAIR VALUE
----------------------------  ---------   ---------------
Nonvested at January 1, 2007    165,868        $22.02
Granted                          53,129        $21.69
Vested during period            (51,002)       $22.74
Forfeited                       (28,922)       $21.43
                                -------
Nonvested at March 31, 2007     139,073        $21.75
                                -------
Granted                              --            --
Vested during period                 --            --
Forfeited                        (1,160)       $21.39
                                -------
Nonvested at June 30, 2007      137,913        $21.75
                                =======

(4) GOODWILL

The changes in the carrying amount of goodwill for the six months ended June 30, 2007, are as follows:

                               Human Health
                                  Segment
                               ------------
Balance as of January 1, 2007  $     32,573
Translation effect                      646
                               ------------
Balance as of June 30, 2007    $     33,219
                               ============

(5) INCOME TAXES

The Company recorded tax expense of $1,971 and a benefit of $392 in the three and six months ended June 30, 2007, respectively, compared to tax expense of $3,424 and $5,924 in the three and six months ended June 30, 2006, respectively. This change is due to the change in geographic mix of pre-tax earnings, as well as the recognition of a tax benefit in continuing operations as a result of the sale of the Bioproducts and Biopharma segments in the first quarter of 2007.

The Company maintains a full valuation allowance against its domestic, and certain foreign, net deferred tax assets and will continue to do so until an appropriate level of profitability is sustained or tax strategies can be developed that would enable the Company to conclude that it is more likely than not that a portion of these net deferred assets would be realized. As such, improvements in domestic, and certain foreign, pre-tax income in the future may result in these tax benefits ultimately being realized. However, there is no assurance that such improvements will be achieved.

8

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(5) INCOME TAXES (CONTINUED)

The Company has adopted the provisions of FIN 48 effective January 1, 2007.

As of January 1, 2007 the Company had reserves of approximately $2,024 for uncertain tax positions that were accounted for in the Company's non-current liabilities and includes estimated cumulative interest and penalties of $414. The Company also had unrecognized tax benefits of $2,000 for certain tax attributes which had full valuation allowances. The net effect of this is a decrease to the gross deferred tax assets and a corresponding decrease to the related valuation allowance with no effect to beginning retained earnings. There was no interest component related to these items. Consistent with prior periods, the company will recognize interest and penalties within its income tax provision. The total unrecognized tax benefit of $4,024, if recognized, would impact the effective tax rate.

The Company has recently closed an audit of its consolidated U.S. operations for the periods 2001- 2003. Although not currently under examination by the IRS, the Company is subject to examination for the years 2004 through 2006. It is also subject to exams in foreign jurisdictions for periods as early as 2002 and beyond in its significant non-U.S. jurisdictions.

The Company is also subject to audit in various states (for various years) in which it files income tax returns. Past audits have not resulted in material adjustments. Audits for New Jersey and Maine have recently been concluded with no material changes. Open years for these states are 2004 and 2005 forward, respectively. An audit for the state of Maryland for 2001-2004 was also concluded recently with no material changes.

The Company anticipates a net decrease of approximately $200 to $300 for unrecognized tax benefits, which would positively impact the provision for income taxes, in the next 12 months mainly due to the expiration of a statute of limitation period.

(6) NET INVENTORIES

Inventories are stated at the lower of cost, determined on a first-in, first-out basis, or market.

Net inventories at June 30, 2007 and December 31, 2006 consist of the following:

                  June 30,   December 31,
                    2007         2006
                 ----------  ------------
Finished goods   $   26,685  $     23,792
Work in process      21,315        15,540
Raw materials         9,008        11,696
Supplies              3,117         2,865
                 ----------  ------------
   Total         $   60,125  $     53,893
                 ==========  ============

9

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(7) LONG-TERM DEBT

In February 2007, proceeds from the sale of the Bioproducts and Biopharma segments, as discussed in Note 14, were used to repay all outstanding debt on the credit facility. Due to this repayment, $821 was recorded in interest expense, in continuing operations, in the first quarter of 2007 related to the acceleration of unamortized origination fees. In April 2007, the Company entered into a $200,000 five-year Syndicated Senior Revolving Credit Facility which expires in April 2012. The Company pays interest on this credit facility at LIBOR plus 1.25% - 2.00% based upon certain measurements of the Company's financial performance. The credit facility also includes financial covenants regarding interest coverage and leverage ratios. The Company was in compliance with all financial covenants at June 30, 2007. At June 30, 2007 there was $85,700 outstanding under this credit facility.

(8) RESTRUCTURING CHARGES

The Company announced plans to eliminate certain employee positions at the corporate office upon completion of the sale of the Bioproducts and Biopharma segments. This plan will include certain one-time benefits for employees terminated and is expected to be completed before the end of 2007. During the three months ended June 30, 2007, the Company recognized expense of $1,901, consisting of $1,817 which will be paid in cash and $84 for stock based compensation and other professional fees. For the six months ended June 30, 2007, the Company recognized expense of $3,583, consisting of $3,407 which will be paid in cash and $176 for stock based compensation and other professional fees. The Company expects the total charge for the program to be approximately $4,000, substantially all of which will be paid in cash. The Company anticipates annual cost savings related to the elimination of all these positions to be approximately $5,200.

The following table reflects the activity related to the severance reserve through June 30, 2007:

                                                   2007 Activity
                            January 1, 2007  ------------------------   June 30, 2007
                            Reserve Balance   Expense   Cash Payments  Reserve Balance
                            ---------------  ---------  -------------  ---------------
Employee termination costs  $            --  $   3,407           (349) $         3,058
                            ===============  =========  =============  ===============

(9) STOCKHOLDERS' EQUITY

On May 3, 2007, the Company paid a special dividend of $14.00 per share to its shareholders resulting in a reduction in stockholders' equity of $403,026. The effect on stockholders' equity was a reduction to retained earnings of $233,244, representing total accumulated earnings as of the date of declaration, with the remainder representing a return of capital of $169,782. Cash disbursements were $401,367 and $1,659 was accrued related to dividends on unvested restricted stock. The Company also announced that it will no longer pay a quarterly dividend.

10

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(10) COMPREHENSIVE INCOME

The following table shows the components of comprehensive income for the three and six months ended June 30, 2007 and 2006:

                                                                 Three months ended             Six months ended
                                                                       June 30,                      June 30,
                                                               ----------------------       -----------------------
                                                                 2007          2006           2007           2006
                                                               -------       --------       ---------      --------
Net income/(loss)                                              $ 2,274       $    976       $ 207,490      $   (429)
Foreign currency translation                                     2,966          9,596           3,195        13,336
Reclassification adjustment for gain on disposition of
business on foreign currency translation included in
net income                                                          --             --            (483)           --
Unrealized (loss)/gain on hedging contracts, net of tax           (122)           250             (45)          374
Unrealized gain/(loss) on available-for-sale securities              5           (415)           (442)         (171)

Reclassification adjustment for net realized loss/(gain)
on available-for-sale securities included in net income             64             --            (670)          --
Pension, net of tax                                                193             --             592           --
Reclassification adjustment for loss on disposition of
business - pension, included in net income                                         --           1,320
                                                               -------       --------       ---------      --------
   Total                                                       $ 5,380       $ 10,407       $ 210,957      $ 13,110
                                                               =======       ========       =========      ========

During the six months ended June 30, 2007 the Company sold two available-for-sale securities. For purposes of computing gains or losses, cost is identified on a specific identification basis. As of December 31, 2006 the amount recorded in accumulated other comprehensive income ("AOCI") was a gain of $1,117, net of tax, which was reclassed out of AOCI upon the sale of the securities and the Company recorded a net gain of $670 to other income at the actual sale dates. The Company also realized a gain of $483 and a loss of $1,320 for foreign currency translation and pension, respectively, related to the sale of the Bioproducts and Biopharma segments, both recorded as part of the gain on sale within discontinued operations.

11

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(11) RETIREMENT PLANS AND OTHER POSTRETIREMENT BENEFITS

Domestic Pension Plans

The components of net periodic pension cost for the Company's domestic plans for the three and six months ended June 30, 2007 and 2006 are as follows:

                                                                 Three months ended             Six months ended
                                                                       June 30,                      June 30,
                                                               ----------------------       -----------------------
                                                                 2007          2006           2007           2006
                                                               -------       --------       ---------      --------
COMPONENTS OF NET PERIODIC BENEFIT COST
Service cost                                                   $   222       $    729       $     557      $  1,458
Interest cost                                                      900            858           1,798         1,716
Expected return on plan assets                                    (937)          (746)         (1,858)       (1,492)
Amortization of prior service costs                                 68             11              73            22
Recognized actuarial loss                                           52            180             104           360
Curtailments                                                        77             --             414            --
                                                               -------       --------       ---------      --------
Net periodic benefit cost                                      $   382       $  1,032       $   1,088      $  2,064
                                                               =======       ========       =========      ========

The sale of the Bioproducts and Biopharma segments in February 2007 required the Company to recognize a curtailment charge of $337 in the three months ended March 31, 2007, which is recorded in discontinued operations.

In April 2007, the Board of Directors of the Company approved the suspension of the domestic pension plans and Supplemental Executive Retirement Plan ("SERP") plan effective August 31, 2007. As a result, the Company was required to recognize a curtailment charge of $77 in the three months ended June 30, 2007.

The Company expects to contribute approximately $4,679 in cash to its two U.S. defined-benefit plans in 2007.

The components of net periodic benefit cost for the Company's SERP Plan for the three and six months ended June 30, 2007 and 2006 is as follows:

                                                                 Three months ended             Six months ended
                                                                       June 30,                      June 30,
                                                               ----------------------       -----------------------
                                                                 2007          2006           2007           2006
                                                               -------       --------       ---------      --------
COMPONENTS OF NET PERIODIC BENEFIT COST
Service cost                                                   $     5       $     55       $      43      $    110
Interest cost                                                       75             63             149           126
Amortization of prior service cost                                   1              1               1             2
Recognized actuarial loss                                            4              6               8            12
Curtailments                                                         4             --              15            --
                                                               -------       --------       ---------      --------
Net periodic benefit cost                                      $    89       $    125       $     216      $    250
                                                               =======       ========       =========      ========

12

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(11) RETIREMENT PLANS AND OTHER POSTRETIREMENT BENEFITS (CONTINUED)

International Pension Plans

The components of net periodic pension cost for the Company's international plan for the three and six months ended June 30, 2007 and 2006 are as follows:

                                                                 Three months ended             Six months ended
                                                                       June 30,                      June 30,
                                                               ----------------------       -----------------------
                                                                 2007          2006           2007           2006
                                                               -------       --------       ---------      --------
COMPONENTS OF NET PERIODIC BENEFIT COST
Service cost                                                   $   111       $    128       $     222      $    256
Interest cost                                                      160            128             320           256
Amortization of unrecognized net obligation                         --             (8)             --           (16)
Recognized actuarial (gain)/loss                                   (17)            17             (34)           34
Amortization of prior service cost                                  (2)            (1)             (4)           (2)
                                                               -------       --------       ---------      --------
Net periodic benefit cost                                      $   252       $    264       $     504      $    528
                                                               =======       ========       =========      ========

Other Postretirement Benefits

The components of net periodic benefit cost for the three and six months ended June 30, 2007 and 2006 are as follows:

                                                                 Three months ended             Six months ended
                                                                       June 30,                      June 30,
                                                               ----------------------       -----------------------
                                                                 2007          2006           2007           2006
                                                               -------       --------       ---------      --------
COMPONENTS OF NET PERIODIC BENEFIT COST
Service cost                                                   $     5       $     16       $      10      $     32
Interest cost                                                       27             34              54            68
Actuarial loss recognized                                           17             33              34            66
Amortization of unrecognized prior service cost                    (39)           (45)            (78)          (90)
                                                               -------       --------       ---------      --------
Net periodic benefit cost                                      $    10       $     38       $      20      $     76
                                                               =======       ========       =========      ========

13

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(12) SEGMENT INFORMATION

The Company classifies its non-corporate business activities into one reportable segment: Human Health, consisting of active pharmaceutical ingredients and pharmaceutical intermediates produced under Food and Drug Administration cGMP for use in the production of prescription and over-the-counter drug products and other fine custom chemicals derived from organic chemistry.

Information as to the operations of the Company is set forth below. Cambrex evaluates performance based on gross profit and operating profit. The Company allocates certain corporate expenses to the Human Health segment.

Two customers each account for 10% of consolidated gross sales in the three and six months ended June 30, 2007. One customer in the three months ended June 30, 2006 and two customers in the six months ended June 30, 2006 each account for 10% of consolidated gross sales. One customer is a pharmaceutical company with which a long-term sales contract is in effect that is scheduled to expire at the end of 2008. The Company has agreed in principle to extend the contract to 2013 which will result in lower profitability for sales under this arrangement in 2007 and 2008. Formal negotiations are complete and the Company is awaiting signature of the contract. The second customer is a distributor representing multiple customers.

The following is a summary of business segment information:

                                 Three months ended            Six months ended
                                      June 30,                     June 30,
                              -----------------------      ------------------------
                                2007          2006           2007           2006
                              ---------     ---------      ---------      ---------
Gross Sales:
Human Health                  $  63,081     $  63,031      $ 128,078      $ 117,151
                              ---------     ---------      ---------      ---------
                              $  63,081     $  63,031      $ 128,078      $ 117,151
                              =========     =========      =========      =========
Gross Profit:
Human Health                  $  23,938     $  22,440      $  48,333      $  41,525
                              ---------     ---------      ---------      ---------
                              $  23,938     $  22,440      $  48,333      $  41,525
                              =========     =========      =========      =========
Operating Profit/(Loss):
Human Health                  $  14,160     $  13,745      $  28,916      $  24,805
Corporate                       (10,204)      (10,422)       (43,324)       (18,237)
                              ---------     ---------      ---------      ---------
                              $   3,956     $   3,323      $ (14,408)     $   6,568
                              =========     =========      =========      =========
Capital Expenditures:
Human Health                  $   6,272     $   5,306      $  11,697      $   9,581
Corporate                            24            42             77             57
                              ---------     ---------      ---------      ---------
                              $   6,296     $   5,348      $  11,774      $   9,638
                              =========     =========      =========      =========
Depreciation:
Human Health                  $   4,682     $   4,614      $   9,414      $   9,111
Corporate                            66           253            167            503
                              ---------     ---------      ---------      ---------
                              $   4,748     $   4,867      $   9,581      $   9,614
                              =========     =========      =========      =========

14

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(12) SEGMENT INFORMATION (CONTINUED)

                                             June 30,      December 31,
                                               2007            2006
                                            ----------     ------------
Total Assets:
Human Health                                $  294,879     $    286,437
Corporate                                       41,756           38,264
Assets of discontinued operations                   --          281,675
                                            ----------     ------------
                                            $  336,635     $    606,376
                                            ==========     ============

(13) CONTINGENCIES

The Company is subject to various investigations, claims and legal proceedings covering a wide range of matters that arise in the ordinary course of its business activities. The Company continually assesses all known facts and circumstances as they pertain to all legal and environmental matters and evaluates the need for reserves and disclosures as deemed necessary based on these facts and circumstances and as such facts and circumstances develop. These matters, either individually or in the aggregate, could have a material adverse effect on the Company's financial condition, operating results and cash flows in a future reporting period.

Environmental

In connection with laws and regulations pertaining to the protection of the environment, the Company and its subsidiaries are a party to several environmental proceedings and remediation investigations and cleanups and, along with other companies, has been named a potentially responsible party ("PRP") for certain waste disposal sites ("Superfund sites"). Additionally, as discussed in the "Sale of Rutherford Chemicals" section of this Note, the Company has retained the liability for certain environmental proceedings, associated with the Rutherford Chemicals business.

Each of these matters is subject to various uncertainties, and it is possible that some of these matters will be decided unfavorably against the Company. The resolution of such matters often spans several years and frequently involves regulatory oversight or adjudication. Additionally, many remediation requirements are not fixed and are likely to be affected by future technological, site, and regulatory developments. Consequently, the ultimate extent of liabilities with respect to such matters, as well as the timing of cash disbursements cannot be determined with certainty.

In matters where the Company has been able to reasonably estimate its liability, the Company has accrued for the estimated costs associated with the study and remediation of Superfund sites not owned by the Company and the Company's current and former operating sites. These accruals were $5,124 and $4,862 at June 30, 2007 and December 31, 2006, respectively. The modest increase in the accrual includes payments of $276. The impact of currency was minimal. Based upon currently available information and analysis, the Company's current accrual represents management's best estimate of the probable and estimable costs associated with environmental proceedings including amounts for legal and investigation fees where remediation costs may not be estimable at the reporting date.

15

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(13) CONTINGENCIES (CONTINUED)

As a result of the sale of the Bayonne, New Jersey facility (see "Sale of Rutherford Chemicals" section of this Note), The Company became obligated to investigate site conditions and conduct required remediation under the New Jersey Industrial Site Recovery Act. The Company completed a preliminary assessment of the site and submitted the preliminary assessment to the New Jersey Department of Environmental Protection ("NJDEP"). The preliminary assessment identified potential areas of concern based on historical operations and sampling of such areas commenced. The Company has completed a second phase of sampling and determined that a third phase of sampling is necessary to determine the extent of contamination and any necessary remediation. The results of the completed and proposed sampling, and any additional sampling deemed necessary, will be used to develop an estimate of the Company's future liability for remediation costs, if any. The Company submitted its plan for the third phase of sampling to the NJDEP during the fourth quarter of 2005. The sampling will commence upon approval of the sampling plan.

The Company's Cosan subsidiary conducted manufacturing operations in Clifton, New Jersey from 1968 until 1979. Prior to the acquisition of Cosan by the Company, the operations were moved to another location and thereafter Cambrex purchased the business. In 1997, Cosan entered into an Administrative Consent Order with the NJDEP. Under the Administrative Consent Order, Cosan was required to complete an investigation of the extent of the contamination related to the Clifton site and conduct remediation as may be necessary. During the third quarter of 2005, the Company completed the investigation related to the Clifton site, which extends to adjacent properties. The results of the investigation caused the Company to increase its related reserves by $1,300 in 2005 based on the proposed remedial action plan. The Company submitted the results of the investigation and proposed remedial action plan to the NJDEP. In late 2006, the NJDEP requested that an additional investigation be conducted at the site. The Company submitted its plan for additional work to the NJDEP in April 2007 and will commence such additional work upon approval of the plan. The Company estimated that the additional work will cost approximately $240, and as such, increased the related reserve by that amount.

In March 2006, the Company received notice from the United States Environmental Protection Agency ("USEPA") that two former operating subsidiaries are considered PRPs at the Berry's Creek Superfund Site, Bergen County, New Jersey. The operating companies are among many other PRPs that were listed in the notice. Pursuant to the notice, the PRPs have been asked to perform a remedial investigation and feasibility study of the Berry's Creek Site. The Company has met with the other PRPs. Both operating companies joined the group of PRPs and filed a joint response to the USEPA agreeing to jointly negotiate to conduct or fund (along with other PRPs) an appropriate remedial investigation and feasibility study of the Berry's Creek Site. At this time it is too early to predict the extent of any liabilities. However, reserves have been established to cover anticipated initial costs related to the site.

The Company is involved in other matters where the range of liability is not reasonably estimable at this time and it is not determinable when information will become available to provide a basis for adjusting or recording an accrual, should an accrual ultimately be required.

Litigation and Other Matters

Mylan Laboratories

In 1998 the Company and its subsidiary Profarmaco S.r.l. (currently known as Cambrex Profarmaco Milano S.r.l.") ("Profarmaco") were named as defendants
(along with Mylan Laboratories, Inc. ("Mylan")

16

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(13) CONTINGENCIES (CONTINUED)

and Gyma Laboratories of America, Inc., Profarmaco's distributor in the United States) in a proceeding instituted by the Federal Trade Commission ("FTC") in the United States District Court for the District of Columbia (the "District Court"). Suits were also commenced by several State Attorneys' General. The suits alleged violations of the Federal Trade Commission Act arising from exclusive license agreements between Profarmaco and Mylan covering two active pharmaceutical ingredients ("APIs"). The FTC and Attorneys' General suits were settled in February 2001, with Mylan (on its own behalf and on behalf of Profarmaco and Cambrex) agreeing to pay over $140,000 and with Mylan, Profarmaco and Cambrex agreeing to monitor certain future conduct.

The same parties including the Company and Profarmaco have also been named in purported class action complaints brought by private plaintiffs in various state courts on behalf of purchasers of the APIs in generic form, making allegations similar to those raised in the FTC's complaint and seeking various forms of relief including treble damages.

In April 2003, Cambrex reached an agreement with Mylan under which Cambrex would contribute $12,415 to the settlement of litigation brought by a class of direct purchasers. In exchange, Cambrex and Profarmaco received from Mylan a release and full indemnity against future costs or liabilities in related litigation brought by purchasers, as well as potential future claims related to this matter. Cambrex recorded an $11,342 charge (discounted to the present value due to the five year pay-out) in the first quarter of 2003 as a result of this settlement. In accordance with the agreement $10,815 has been paid through June 30, 2007, with the remaining $1,600 to be paid next year.

Vitamin B-3

In May 1998, the Company's subsidiary, Nepera, which formerly operated the Harriman facility and manufactured and sold niacinamide ("Vitamin B-3"), received a Federal Grand Jury subpoena for the production of documents relating to the pricing and possible customer allocation with regard to that product. In 2000, Nepera reached an agreement with the government as to its alleged role in Vitamin B-3 violations from 1992 to 1995. The Canadian government claimed similar violations. All government suits in the U.S. and Canada have been concluded.

Nepera has been named as a defendant, along with several other companies, in a number of private civil actions brought on behalf of alleged purchasers of Vitamin B-3. The actions seek injunctive relief and unspecified but substantial damages. All cases have been settled within established reserve amounts.

Settlement documents are expected to be finalized and payments are expected to be made during the next several months. The balance of the reserves recorded within accrued liabilities related to this matter was $1,579 as of June 30, 2007.

Sale of Rutherford Chemicals

The Company completed the sale of its Rutherford Chemicals business in November 2003. Under the agreement for the sale ("Purchase Agreement"), the Company provided standard representations and warranties and included various covenants concerning the business, operations, liabilities and financial condition of the Rutherford Chemicals business ("Rutherford Business"). Under the Purchase Agreement, the Company indemnified the purchasers of the Rutherford Business ("Buyers") for breaches of representations, warranties and covenants. The Company also retained the liabilities associated with

17

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(13) CONTINGENCIES (CONTINUED)

existing general litigation matters related to the Rutherford Business. With respect to certain pre-closing environmental matters, the Company retained the responsibility for: (i) certain existing matters including violations and off-site liabilities; (ii) completing the on-going remediation at the New York facility under a Record of Decision ("ROD"); and (iii) completing the obligation to investigate site conditions and conduct required remediation under the provisions of the New Jersey Industrial Site Recovery Act ("ISRA"), an obligation that was triggered by the sale of the Rutherford Business. With respect to all other pre-closing environmental liabilities, whether known or unknown, costs would be allocated subject to certain limitations defined in the Purchase Agreement. The Company accrued for exposures which are deemed probable and estimable related to the retained matters.

In April 2006, the Company received a summons and complaint (the "Complaint") from the Buyers, which was filed in the Supreme Court of the State of New York, County of New York. In the Complaint, the Buyers sought indemnification, declaratory and injunctive relief for alleged (i) breaches of various representations, warranties and covenants, related to structures, buildings and equipment at each of the purchased facilities and, in addition, was responsible for a related third party claim; and (ii) was obligated to conduct certain environmental remediation at four of the five Rutherford Business facilities. The Company denied the allegations, filed counterclaims and has been vigorously defending the matter.

On July 30, 2007 the Company entered into a Settlement Agreement and Release (the "Settlement Agreement") and a related Environmental Escrow Agreement (the "Escrow Agreement") settling litigation which had been commenced by the Buyers by the filing of the Complaint in April 2006.

Under the Settlement Agreement, the parties agreed to make the following payments:

- Within 30 days from the date of the Settlement Agreement, (i) the Company agreed to pay the Buyers the sum of $636 in reimbursement for past remediation expenses at the Rutherford Business facilities; and (ii) the Buyers agreed to pay the Company 400 British pounds (approximately $813) for reimbursement of certain tax refunds received from United Kingdom taxing authorities.

- The Buyers agreed to pay to an account (the "Escrow Account") created under the Escrow Agreement the sum of $3,149 plus interest subsequent to September 30, 2007, representing the amount owed on a Subordinated Promissory Note issued as consideration under the Purchase Agreement. The sum of $3,149 is to be paid in full no later than February 28, 2008 ("Final Note Payment").

- The Company agreed to pay to the Escrow Account approximately $4,400 within 30 days after the Buyers' Final Note Payment.

The Escrow Account can be used only for costs arising from the remediation of environmental contamination at the Rutherford Business facilities. The Company has the right to object to any use of the funds in the Escrow Account for non-remediation purposes, pursuant to an accelerated dispute resolution process involving the parties' appointment of a Special Master.

Under the Settlement Agreement, the parties waive and extinguish all rights under the Purchase Agreement to seek damages or any other remedy for any other obligation contained in the Purchase Agreement as they relate to environmental liabilities, including damages related to pre-closing ownership or

18

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(13) CONTINGENCIES (CONTINUED)

operation of the Rutherford Business facilities, compliance with environmental laws, and all remediation at the Rutherford Business facilities, except for certain matters which the Company specifically retained, namely (i) the off-site treatment, storage and disposal of hazardous materials occurring before the November 10, 2003 closing of the Purchase Agreement, (ii) liability arising from the pre-closing sales of products, (iii) the completion of on-going remediation at the Nepera facility under a ROD, and (iv) completion of on-going remediation at the Bayonne facility under ISRA. The Buyers, however, retain its contractual obligation not to engage in any conduct that materially increases the Company's costs of completing the remediation under the ROD at the Nepera facility and the ISRA process at the Bayonne facility. The obligations specifically retained by the Company are consistent with its remediation obligations under the Purchase Agreement. The Company has previously accrued for exposures deemed probable and reasonable related to any specifically retained matters.

Further, under the Settlement Agreement, the Buyers and the Company release each other from all claims and counterclaims asserted in the litigation, with the exception of the Company's possible claim that the Buyers' activities have increased the Company's remediation costs at the Nepera facility, which claim the Company will dismiss without prejudice to its right to reassert the claim in the future. The Buyers and the Company also waive all rights and obligations under the Purchase Agreement related to any claims for additional payments under the Purchase Agreement, including the Company's claims for the return of tax refunds, the payment of the Subordinated Note, and any payments under the earn-out provision.

Under the Settlement Agreement, the Company indemnifies and holds harmless the Buyers for damages related to the obligations the Company specifically retained. The Buyers indemnify and hold harmless the Company for certain liabilities, including without limitation those arising from the presence of hazardous materials at any of the Rutherford Business facilities, except for the matters specifically retained by the Company.

The foregoing description is a summary and is qualified in its entirety by the Settlement Agreement, which is filed as an Exhibit to this Quarterly Report on Form 10-Q for the period ending June 30, 2007.

Related to the Settlement Agreement, the Company's second quarter 2007 results include a charge of $4,007, net of tax, recorded in discontinued operations related to this matter.

Class Action Matter

In October 2003, the Company was notified of a securities class action lawsuit filed against Cambrex and five former and current Company officers. Five class action suits were filed with the New Jersey Federal District Court (the "Court"). Discovery in this matter is proceeding. In January 2004, the Court consolidated the cases, designated the lead plaintiff and selected counsel to represent the class. An amended complaint was filed in March 2004. The lawsuit has been brought as a class action in the names of purchasers of the Company's common stock from October 21, 1998 through July 25, 2003. The complaint alleges that the Company failed to disclose in a timely fashion the January 2003 accounting restatement and subsequent SEC investigation, as well as the loss of a significant contract at the Baltimore facility.

The Company filed a Motion to Dismiss in May 2004. Thereafter, the plaintiff filed a reply brief and in October 2005, the Court denied the Company's Motion to Dismiss. The Company continues to believe that the complaints are without merit and will vigorously defend against them. As such, the Company has recorded no reserves related to this matter. The Company has reached its deductible under its insurance policy and further costs, expenses and any settlement are expected to be paid by the Company's insurers.

19

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(13) CONTINGENCIES (CONTINUED)

Securities and Exchange Commission ("SEC")

Since 2003, the SEC has been conducting an investigation into the Company's inter-company accounting procedures from the period 1997 through 2001. The investigation began in the first half of 2003 after the Company voluntarily disclosed certain matters related to inter-company accounts for the five-year period ending December 31, 2001 that resulted in the restatement of the Company's financial statements for those years. In late June 2007, this matter was concluded with the issuance by the SEC of a Cease and Desist Order ("Order"). There are no fines or penalties associated with the Order. Under the Order, the Company agreed to undertake certain remedial actions including, for a two year period following the effective date of the Order, having the Company's outside auditor conduct an annual review of its accounting practices related to intercompany transactions and compliance with the Order, with the results of such review being reported to the SEC. The Company has implemented the remedial measures and will continue the reporting and records retention obligations set forth in the Order. This matter may be considered concluded.

Baltimore Litigation

In 2001, the Company acquired the biopharmaceutical manufacturing business in Baltimore (the "Baltimore Business"). The sellers of the Baltimore Business filed suit against the Company alleging that the Company made false representations during the negotiations on which the sellers relied in deciding to sell the business and that the Company breached its obligation to pay additional consideration as provided in the purchase agreement which was contingent on the performance of the Baltimore Business. Management believes the matter to be without merit and continues its defense of this matter. A decision on the Company's Motion for Summary Judgment filed in 2006 is pending.

Other

The Company has commitments incident to the ordinary course of business including corporate guarantees of certain subsidiary obligations to the Company's lenders related to financial assurance obligations under certain environmental laws for remediation, closure and/or third party liability requirements of certain of its subsidiaries and a former operating location; contract provisions for indemnification protecting its customers and suppliers against third party liability for manufacture and sale of Company products that fail to meet product warranties and contract provisions for indemnification protecting licensees against intellectual property infringement related to licensed Company technology or processes.

Additionally, as permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is, or was, serving at the Company's request in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited; however, the Company has a Director and Officer insurance policy that covers a portion of any potential exposure. The Company currently believes the estimated fair value of its indemnification agreements is not significant based on currently available information, and as such, the Company has no liabilities recorded for these agreements as of June 30, 2007.

In addition to the matters identified above, Cambrex's subsidiaries are party to a number of other proceedings.

20

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(14) DISCONTINUED OPERATIONS

On October 27, 2006, the Company sold two businesses within the Human Health segment for nominal consideration. As a result of this transaction, the Company reported a non-cash charge of $23,244 in the fourth quarter of 2006 and these businesses are being reported as discontinued operations in all periods presented.

On February 6, 2007, the Company completed the sale of the businesses that comprise the Bioproducts and Biopharma segments (excluding certain liabilities) to Lonza Group AG for cash consideration of $460,000. As a result of the transaction, the Company recorded a $232,116 gain in the first quarter of 2007 and an additional gain of $3,491 in the second quarter of 2007, which includes a final payment of $3,914 related to a working capital adjustment partially offset by additional deal costs. As a result of the completion of the transaction on February 6, 2007, the Bioproducts and Biopharma segments are being reported as discontinued operations in all periods presented.

On July 30, 2007 the Company entered into a Settlement Agreement and a related Escrow Agreement settling litigation which had been commenced by the purchasers of the Rutherford Business by the filing of the Complaint in April 2006. As a result of this settlement, the Company's second quarter 2007 results include a charge of $4,007, net of tax, recorded in discontinued operations. Refer to Note 13 for a complete discussion on this matter.

The following table reflects revenues and (loss)/income from the discontinued operations:

                                              Three months ended June 30,    Six months ended June 30,
                                             ----------------------------   ----------------------------
                                                 2007            2006           2007           2006
                                             ------------    ------------   ------------    ------------
Revenues                                     $         --    $     60,546   $     20,335    $    126,033
                                             ============    ============   ============    ============
Pre-tax income from operations of
discontinued operations                      $         --    $      2,691   $        545    $      8,259
Gain on sale of Bioproducts and Biopharma
segments                                            3,491              --        235,607              --
Rutherford litigation settlement                   (4,602)             --         (4,602)             --
                                             ------------    ------------   ------------    ------------
(Loss)/income from discontinued operations
before income taxes                          $     (1,111)   $      2,691   $    231,550    $      8,259
(Benefit)/provision for income taxes                 (930)          1,367         12,072           3,408
                                             ------------    ------------   ------------    ------------
(Loss)/income from discontinued
operations, net of tax                       $       (181)   $      1,324   $    219,478    $      4,851
                                             ============    ============   ============    ============

21

CAMBREX CORPORATION AND SUBSIDIARIES
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
(dollars in thousands, except share data)

(14) DISCONTINUED OPERATIONS (CONTINUED)

The following table reflects the carrying amount of the assets and liabilities as of December 31, 2006 for the businesses that were sold on February 6, 2007:

                                            December 31,
                                               2006
                                           -------------
Assets:
Cash                                       $          --
Accounts receivable, net                          35,460
Inventories, net                                  40,708
Other current assets                               3,215
Property, plant and equipment, net                85,162
Intangibles, net                                 115,562
Other assets                                       1,568
                                           -------------
Total assets held for sale                       281,675
Liabilities:
Accounts payable and accrued liabilities          31,965
Other current liabilities                          1,436
Long-term debt                                     3,627
Other liabilities                                 20,581
                                           -------------
Total liabilities held for sale            $      57,609
                                           -------------
Net assets held for sale                   $     224,066
                                           =============

22

CAMBREX CORPORATION AND SUBSIDIARIES
(dollars in thousands, except share data)

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

EXECUTIVE OVERVIEW

The Company's business consists of one segment - Human Health. The Human Health segment is primarily comprised of active pharmaceutical ingredients derived from organic chemistry and pharmaceutical intermediates.

The following significant events occurred during the second quarter of 2007 which affected reported operating profit:

- A charge of $4,564 recorded within operating expenses for strategic alternative costs.

- A charge of $1,901 recorded within operating expenses for restructuring expenses.

RESULTS OF OPERATIONS

COMPARISON OF SECOND QUARTER 2007 VERSUS SECOND QUARTER 2006

Gross sales in the second quarter 2007 of $63,081 were equal to sales in the second quarter 2006. Gross sales were favorably impacted 3.5% due to exchange rates reflecting a weaker U.S. dollar.

Within the Human Health segment, sales of active pharmaceutical ingredients ("APIs") of $50,143 were $5,103 or 11.3% above the second quarter 2006 primarily due to higher volumes of APIs and proprietary products partially offset by lower pricing. Sales of pharmaceutical intermediates of $5,522 were $3,564 or 39.2% below the second quarter 2006 primarily due to fluctuations in customer order patterns for custom development projects, and a strong second quarter last year for custom development sales. Sales of other Human Health products of $7,416 were $1,489 or 16.7% below the second quarter 2006 primarily due to weaker demand of feed additives.

Human Health gross margins increased to 37.9% in the second quarter 2007 from 35.6% in the second quarter 2006. This increase is primarily due to favorable product mix and foreign currency exchange partially offset by lower pricing.

The following table reflects sales by geographic area for the three months ended June 30, 2007 and 2006:

                         2007         2006
                       ---------   ---------
North America          $  22,829   $  26,704
Europe                    36,010      33,336
Asia                       2,499       1,679
Other                      1,743       1,312
                       ---------   ---------
   Total Gross Sales   $  63,081   $  63,031
                       =========   =========

Selling, general and administrative expenses of $10,556 or 16.7% of gross sales in the second quarter 2007 decreased from $14,998, or 23.8% in the second quarter 2006. The decrease in expense is due mainly to lower administration expenses, primarily personnel and related benefit costs, insurance costs due to the renewing of several policies and audit fees partially offset by the impact of foreign currency exchange.

23

RESULTS OF OPERATIONS (CONTINUED)

COMPARISON OF SECOND QUARTER 2007 VERSUS SECOND QUARTER 2006 (CONTINUED)

The Company announced plans to eliminate certain employee positions at the corporate office upon completion of the sale of the Bioproducts and Biopharma segments. This plan will include certain one-time benefits for employees terminated and is expected to be completed before the end of 2007. Costs related to these plans are recorded on the restructuring expenses line on the income statement. The Company recognized expense of $1,901 during the second quarter 2007, and expects the total restructuring charge to be approximately $4,000, substantially all of which will be in cash. The Company anticipates annual cost savings related to the elimination of all these positions to be approximately $5,200.

Strategic alternative costs include costs that the Company has incurred related to the decision to sell the Bioproducts and Biopharma segments in February 2007. These costs are not considered part of the restructuring program or a part of discontinued operations under current accounting guidance. The Company has recorded approximately $984 during the second quarter of 2007 which became payable under change of control agreements between the Company and four of its current or former executives due to the sale of the Bioproducts and Biopharma segments. The Company will recognize additional expense in future quarters for the recognition of interest as well as the potential for changes in estimates. Substantially all of this charge will be paid in cash. The exact timing of the payments is uncertain at this time but the majority are expected to be in 2008.

Also included in strategic alternative costs in the current quarter is $1,044 of retention bonuses. This includes amounts payable to certain current employees for continued employment, generally through September 30, 2007. The Company is recognizing this cost ratably over the applicable service period and anticipates a total charge related to such retention bonuses of approximately $3,200. Additional costs including those associated with the modification of employee stock options due to the payment of the special dividend in connection with the divestiture amounted to approximately $2,536 during the quarter. Strategic alternative costs for the second quarter 2006 of $1,042 consist of external advisor costs related to divestitures.

Research and development expenses of $2,961 were 4.7% of gross sales in the second quarter 2007, and were relatively flat compared to expenses of $3,077 or 4.9% of gross sales in the second quarter 2006. The impact of foreign currency exchange was negligible.

Operating profit in the second quarter 2007 was $3,956 compared to $3,323 in the second quarter 2006. The results reflect higher gross margins as discussed above, partially offset by higher operating expenses due to strategic alternative and restructuring costs.

Net interest income was $871 in the second quarter 2007 compared to net interest expense of $122 in the second quarter 2006. These results primarily reflect lower average debt from use of the proceeds from the sale of the Bioproducts and Biopharma segments, partially offset by higher interest rates. Interest income was also higher in the second quarter of 2007 compared to 2006 due to interest earned on the proceeds from the sale of the Bioproducts and Biopharma segments. The average interest rate on debt was 7.5% in the second quarter 2007 versus 5.8% in the second quarter of 2006.

The effective tax rate for the second quarter 2007 was 44.5% compared to 111.3% in the second quarter 2006. The tax provision in the second quarter 2007 decreased to $1,971 compared to $3,424 in the second quarter of 2006. This change is due to the geographic mix of pre-tax earnings, as well as the recognition of a $1,548 tax benefit in continuing operations for the second quarter 2007 as a result of the sale of the Bioproducts and Biopharma segments in the first quarter of 2007. The Company maintains a full valuation allowance against its domestic, and certain foreign, net deferred tax assets and will continue to do so until an appropriate level of profitability is sustained or tax strategies can be developed that would enable the Company to conclude that it is more likely than not that a portion of these net deferred assets would be

24

RESULTS OF OPERATIONS (CONTINUED)

COMPARISON OF SECOND QUARTER 2007 VERSUS SECOND QUARTER 2006 (CONTINUED)

realized. As such, improvements in domestic, and certain foreign, pre-tax income in the future may result in these tax benefits ultimately being realized. However, there is no assurance that such improvements will be achieved.

Income from continuing operations in the second quarter 2007 was $2,455, or $0.08, per diluted share versus a loss of $348, or $0.01 per diluted share in the same period a year ago.

The Company adopted Financial Accounting Standards Board ("FASB") Interpretation No. 48, Accounting for Uncertainty in Income Taxes -- an interpretation of FASB Statement No. 109 ("FIN 48") effective January 1, 2007. This interpretation clarified the accounting for uncertainty in income tax positions and required the Company to recognize in the consolidated financial statements the impact of a tax position that is more likely than not to be sustained upon examination based on the technical merits of the position. The effect of adopting the interpretation was not material. Refer to Note 5 for further discussion.

The Company adopted FASB Staff Position ("FSP") No. AUG AIR-1 "Accounting for Planned Major Maintenance Activities" effective January 1, 2007. This FSP amended certain provisions of APB Opinion No. 28 "Interim Financial Reporting". This FSP prohibited the use of the accrue-in-advance method of accounting for planned major maintenance activities in annual and interim reporting periods. The adoption of this FSP had an immaterial impact on the Company's financial position and results of operations.

COMPARISON OF FIRST SIX MONTHS 2007 VERSUS FIRST SIX MONTHS 2006

Gross sales for the first six months of 2007 increased 9.3% to $128,078 from $117,151 in the first six months of 2006. Gross sales were favorably impacted 4.4% due to exchange rates reflecting a weaker U.S. dollar in the first six months of 2007 versus 2006.

The following table shows sales by geographic area for the six months ended June 30, 2007 and 2006:

                          2007         2006
                       ----------   ----------
North America          $   45,302   $   43,825
Europe                     74,577       67,174
Asia                        4,506        3,021
Other                       3,693        3,131
                       ----------   ----------
   Total Gross Sales   $  128,078   $  117,151
                       ==========   ==========

Within the Human Health segment, sales of APIs of $98,485 were $13,048 or 15.3% above the first six months of 2006 primarily due to higher volumes of APIs partially offset by lower pricing. Sales of pharmaceutical intermediates of $13,580 were $2,016 or 12.9% below the first six months of 2006 primarily due to fluctuations in customer order patterns for custom development projects, and a strong six months last year for custom development sales. Sales of other Human Health products, primarily fine chemicals, of $16,013 were flat when comparing the first six months of 2007 versus 2006.

Human Health gross margins increased to 37.7% in the first six months of 2007 compared to 35.4% in the first six months of 2006. The increase in margins is due to higher sales volume, favorable product mix and a favorable impact due to foreign currency translation partially offset by pricing pressures on custom development products.

25

RESULTS OF OPERATIONS (CONTINUED)

COMPARISON OF FIRST SIX MONTHS 2007 VERSUS FIRST SIX MONTHS 2006 (CONTINUED)

Selling, general and administrative expenses of $25,903 or 20.2% of gross sales in the first six months of 2007 decreased from $27,488 or 23.5% in the first six months of 2006. The decrease in expense is due primarily to lower administration expenses related to personnel costs and audit fees partially offset by higher legal fees and the impact of foreign currency exchange.

The Company announced plans to eliminate certain employee positions at the corporate office upon completion of the sale of the Bioproducts and Biopharma segments. This plan will include certain one-time benefits for employees terminated and is expected to be completed before the end of 2007. Costs related to these plans are recorded on the restructuring expenses line on the income statement. The Company recognized expense of $3,583 during the first six months of 2007, and expects the total charge for the program to be approximately $4,000, substantially all of which will be in cash. The Company anticipates annual cost savings related to the elimination of all these positions to be approximately $5,200.

Strategic alternative costs include costs that the Company has incurred related to the decision to sell the Bioproducts and Biopharma segments in February 2007. These costs are not considered part of the restructuring program or a part of discontinued operations under current accounting guidance. The first six months of 2007 includes charges of $19,172 related to certain benefits which became payable under change of control agreements between the Company and four of its current or former executives due to the sale of the Bioproducts and Biopharma segments. The Company will recognize additional expense in future quarters for the recognition of interest and discounting as well as the potential for changes in estimates. Substantially all of this charge will be paid in cash. The exact timing of the payments is uncertain at this time but is expected to be in 2008.

Also included in strategic alternative costs in the first six months of 2007 is $3,820 of retention bonuses paid in 2007 as a result of the completion of the Bioproducts and Biopharma segments sales transaction on February 6, 2007. In addition, costs of $1,713 are also included related to bonuses payable to certain current employees for continued employment, generally through September 30, 2007. The Company is recognizing this cost ratably over the applicable service period and anticipates a total charge of approximately $3,200. Additional costs including those associated with the payment of the special dividend in connection with the divestiture amounted to approximately $2,989 during the first six months of 2007, $2,417 of which related to a non-cash charge to account for a modification of the exercise price for all outstanding stock options. Strategic alternative costs for the first six months of 2006 of $2,030 consist of external advisor costs related to divestitures.

Research and development expenses of $5,561 or 4.3% of gross sales in the first six months of 2007 were comparable to $5,439 or 4.6% of gross sales in the first six months of 2006.

Operating loss in the first six months of 2007 was $14,408 compared to a profit of $6,568 in the first six months of 2006. The results reflect higher operating expenses due to strategic alternative and restructuring costs partially offset by higher gross margins, as discussed above.

Net interest income was $2,410 in the first six months of 2007 compared to net interest expense of $5,566 in the first six months of 2006 primarily reflecting lower average debt partially offset by higher interest rates. Also included in first six months of 2007 was the acceleration of unamortized origination fees related to the repayment of the credit facility of $821. Included in first six months of 2006 is approximately $5,272 related to the make whole payment of $4,809 and the related acceleration of $463 of unamortized origination fees. Interest income was also higher in the first six months of 2007 compared to 2006 due to interest earned on the proceeds from the sale of the Bioproducts and Biopharma segments. The average interest rate was 6.8% in the first six months of 2007 versus 5.5% in the first six months of 2006.

26

RESULTS OF OPERATIONS (CONTINUED)

COMPARISON OF FIRST SIX MONTHS 2007 VERSUS FIRST SIX MONTHS 2006 (CONTINUED)

The effective tax rate for the first six months of 2007 was 3.2% compared to 679.4% in the first six months of 2006. The tax provision in the first six months of 2007 changed to a benefit of $392 compared to expense of $5,924 in the first six months of 2006. This change is due to the geographic mix of pre-tax earnings, as well as the recognition of an $8,306 tax benefit in continuing operations for the first six months of 2007 as a result of the sale of the Bioproducts and Biopharma segments in the first quarter of 2007. The Company maintains a full valuation allowance against its domestic, and certain foreign, net deferred tax assets and will continue to do so until an appropriate level of profitability is sustained or tax strategies can be developed that would enable the Company to conclude that it is more likely than not that a portion of these net deferred assets would be realized. As such, improvements in domestic, and certain foreign, pre-tax income in the future may result in these tax benefits ultimately being realized. However, there is no assurance that such improvements will be achieved.

LIQUIDITY AND CAPITAL RESOURCES

Cash and cash equivalents increased $7,487 in the first six months of 2007. During the six months ended June 30, 2007, the Company generated cash from operations of $9,604, an increase of $5,616 versus the same period a year ago. The increase in cash flows from operations in the first six months of 2007 versus the first six months of 2006 is due primarily to improved collections of accounts receivable and higher net income, net of non-cash items, partially offset by higher inventory and lower accounts payable.

Cash flows provided by investing activities in the first six months of 2007 of $451,606 primarily reflect proceeds from the sale of the Bioproducts and Biopharma segments. Capital expenditures from continuing operations were $11,774 in the first six months of 2007 as compared to $9,638 in 2006. Part of the funds in 2007 were used for new manufacturing and research and development facilities in Milan, Italy and capital improvements to existing facilities.

Cash flows used in financing activities in the first six months of 2007 of $454,723 include net pay down of debt of $73,157 and dividends paid of $402,200 partially offset by proceeds from stock options exercised of $20,947. In the first six months of 2006 financing activities include a net pay down of debt of $1,729 and dividends paid of $1,604 partially offset by proceeds from stock options exercised of $1,267.

The Company used the proceeds from the sale of the Bioproducts and Biopharma segments, which closed during the first quarter of 2007, to repay outstanding debt and in May 2007, paid a special dividend of $14.00 per share, totaling $401,367. Approximately $94,000 was borrowed from the Company's new five-year, $200,000 credit facility to pay the dividend. The Company also discontinued its quarterly dividend payment and will instead allocate these cash outlays to support its growth initiatives. During the first six months of 2006, the Company paid cash dividends of $0.06 per share.

FORWARD-LOOKING STATEMENTS

This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions are used in connection with any discussion of future financial and/or operating performance. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this Form 10-Q. Any

27

forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and/or regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, changes in foreign exchange rates, uncollectible receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, lack of suitable raw materials or packaging materials, the Company's ability to receive regulatory approvals for its products and the accuracy of the Company's current estimates with respect to its earnings and profits for tax purposes in 2007. Any forward-looking statement speaks only as of the date on which it is made, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. New factors emerge from time to time and it is not possible for the Company to predict which will arise. In addition, we cannot assess the impact of each factor on the Company's business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

For further details and a discussion of these and other risks and uncertainties, investors and security holders are cautioned to review the Cambrex 2006 Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other subsequent filings with the U.S. Securities and Exchange Commission, included Current Reports on Form 8-K. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

28

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

There has been no significant change in our exposure to market risk during the first six months of 2007. For a discussion of the Company's exposure to market risk, refer to Part II, Item 7A, "Quantitative and Qualitative Disclosures about Market Risk," contained in the Company's Annual Report on Form 10-K for the period ended December 31, 2006.

ITEM 4. CONTROLS AND PROCEDURES

EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES

The Company maintains a system of disclosure controls and procedures designed to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Securities Exchange Act of 1934 is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls are also designed to reasonably assure that such information is accumulated and communicated to management, including the Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Disclosure controls include components of internal control over financial reporting, which consists of control processes designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles in the United States.

We have carried out an evaluation under the supervision of, and with the participation of, our management, including the Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2007. The Company's management has concluded that the financial statements included in this Form 10-Q are a fair presentation in all material respects the Company's financial position, results of operations and cash flows for the periods presented in conformity with generally accepted accounting principles.

There are inherent limitations to the effectiveness of any system of disclosure controls and procedures, including the possibility of human error and the circumvention or overriding of the controls and procedures. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING.

There were no significant changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting during the quarter ended June 30, 2007.

29

PART II - OTHER INFORMATION

CAMBREX CORPORATION AND SUBSIDIARIES

ITEM 1. LEGAL PROCEEDINGS

See the discussion under Part I, Item 1, Note 13 to the Consolidated Financial Statements.

ITEM 1A. RISK FACTORS

There have been no material changes to our risk factors and uncertainties during the first six months of 2007. For a discussion of the Risk Factors, refer to Part I, Item 1A, "Risk Factors," contained in the Company's Annual Report on Form 10-K for the period ended December 31, 2006.

ITEM 6. EXHIBITS

Exhibits

1. Exhibit 10.10 - Settlement Agreement and Release and Environmental Escrow Agreement dated July 30, 2007 between Rutherford Chemicals LLC, Vertellus Specialties Holdings UK Ltd. (formerly Rutherford Chemicals UK Ltd.), Vertellus Specialties UK Ltd. (formerly Seal Sands Chemicals Ltd.), and Vertellus Specialties Holdings Corp. (formerly Rutherford Chemicals Holdings Corp.), and Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland Chemicals, Inc., Nepcam, Inc., and Cambrex Ltd.

2. Exhibit 31.1 - CEO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

3. Exhibit 31.2 - CFO Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

4. Exhibit 32.1 - CEO Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

5. Exhibit 32.2 - CFO Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

30

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CAMBREX CORPORATION

                               By   /s/ Gregory P. Sargen
                                    ------------------------------------------
                                    Gregory P. Sargen
                                    Vice President and Chief Financial Officer
                                    (On behalf of the Registrant and as the
                                    Registrant's Principal Financial Officer)

Dated:  August 7, 2007

31

EXHIBIT 10.10

SETTLEMENT AGREEMENT AND RELEASE

This SETTLEMENT AGREEMENT AND RELEASE ("Agreement") is made and entered into as of the 30th day of July, 2007, by and between Rutherford Chemicals LLC, Vertellus Specialties Holdings UK Ltd. (formerly Rutherford Chemicals UK Ltd.), Vertellus Specialties UK Ltd. (formerly Seal Sands Chemicals Ltd.), and Vertellus Specialties Holdings Corp. (formerly Rutherford Chemicals Holdings Corp.) and Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland Chemicals, Inc. (a/k/a Zeeland, Inc.), Nepcam, Inc., and Cambrex Ltd. The signatories to this Agreement will be referred to jointly as the "Parties."

RECITALS:

WHEREAS, certain of the Parties have been engaged in litigation regarding the application of the Asset Purchase Agreement (defined below) in New York State Supreme Court under the caption Rutherford Chemicals LLC et al. v. Cambrex Corporation, et al., Index No. 601176/06; and

WHEREAS, to avoid the expense, uncertainty, and disruption of further litigation, the Parties wish to resolve their disputes regarding the Asset Purchase Agreement and intend this Agreement to effectuate the full, final and complete resolution of the allegations, claims, and causes of action that have been asserted in the Litigation, as defined herein; to further settle and resolve certain additional claims that have not been raised in the Litigation, including but not limited to all claims for payments of the Subordinated Promissory Note as defined in the Asset Purchase Agreement and all additional payments now or in the future that are or might be due and owing under the Asset Purchase Agreement;

NOW, THEREFORE, in consideration of the covenants set forth in this Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:

ARTICLE I
DEFINITIONS

1.1 "Asset Purchase Agreement" or "APA" means the Amended and Restated Asset Purchase Agreement dated as of October 17, 2003, between Rutherford Acquisition Corp. and Cambrex Corporation and the Sellers listed therein, including the document entitled "Documents Executed and Delivered in Connection with the Acquisition of The Rutherford Chemicals Business by Rutherford Acquisition Corp." dated November 10, 2003.

1.2 "Assumed Liabilities" means the liabilities and obligations defined in the APA and set forth on Annex A to the APA.

1.3 "Cambrex" means Defendants Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland, Inc., Nepcam, Inc., and Cambrex Ltd., and all subsidiaries, successors and assigns.


1.4 "Claims" means any and all claims asserted by Rutherford in the Complaint, including but not limited to, all claims for money damages, indemnification, breach of warranty and covenants, attorneys' fees, and all claims for declaratory and injunctive relief.

1.5 "Closing" means the November 11, 2003 closing at which Rutherford Acquisition Corp. concluded the purchase from Cambrex of the Rutherford Facilities, as defined herein.

1.6 "Complaint" means the "Complaint for Indemnification, Breach of Warranty and Covenants, Declaratory and Injunctive Relief" filed in the Supreme Court of the State of New York, County of New York, on April 4, 2006.

1.7 "Counterclaims" means any and all Counterclaims asserted by Cambrex in their Initial Answer and their First and Second Amended Answers and Counterclaims, including but not limited to, all claims for money damages, indemnification, damages or offsets for breach of warranty and covenants, reformation, attorneys' fees, and all claims for declaratory and injunctive relief.

1.8 "Environmental Escrow Agreement" means the agreement entered into by the Parties to this Agreement and that is attached hereto and expressly made a part of this Agreement.

1.9 "Environmental Laws" means all federal, state, local and foreign laws, orders, and regulations relating to pollution or protection of the environment, including, without limitation, ambient air, surface water, groundwater, surface or subsurface strata, sediments, all fish, wildlife, biota and all other natural resources, worker health, preservation or reclamation of natural resources (the "Environment"), or to the management handling, use, generation, treatment, storage, transportation, disposal, manufacture, distribution, formulation, packaging, labeling, releases or threatened releases of, or exposure to, Hazardous Materials, including without limitation: the Comprehensive Environmental Response, Compensation, and Liability Act, 42 U.S.C. Sections 9601 et seq. ("CERCLA"), the Federal Water Pollution Control Act, 33 U.S.C. Sections 1251 et seq.; the Clean Air Act, 42 U.S.C. Sections 7401 et seq.; the Toxic Substances Control Act, 15 U.S.C. Sections 2601 et seq.; the Occupational Safety and Health Act, 29 U.S.C. Sections 651 et seq. (but solely as it relates to the exposure of Hazardous Materials); the Emergency Planning and Community Right-to-Know Act of 1986, 42 U.S.C. Sections 11001 et seq.; the Safe Drinking Water Act, 42 U.S.C. Sections 300(f) et seq.; the Hazardous Materials Transportation Act, 49 U.S.C. Sections 1801 et seq.; the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. Sections 136 et seq.; the Resource Conservation and Recovery Act of 1976 ("RCRA"), 42 U.S.C. Sections 6901 et seq.; the Oil Pollution Act of 1990, 33 U.S.C. Sections 2701 et seq.; and any similar or implementing state or local law, and any non-U.S. laws and regulations of similar import, and all amendments or regulations promulgated thereunder; and any common law doctrine, including without limitation, negligence, nuisance, trespass, personal injury or property damage, to the extent such common laws doctrine relates to or arises out of the presence of, release or threatened release of, or exposure to, Hazardous Materials.

1.10 "Environmental Liabilities" means any and all costs, losses, damages, demands, claims, fines, penalties, assessments, expenses, obligations and liabilities arising in connection with or in any way relating to (a) the ownership or operation of the Rutherford Facilities or the

2

chemicals business operated thereon or associated therewith; or (b) the ownership, operation or condition of the real property located at the Rutherford Facilities, which in either case arise under, are necessary to achieve or maintain compliance with, or relate to (i) the presence, use, generation, storage, transportation, treatment, sale, disposal or release or exposure to any Hazardous Materials at any of the Rutherford Facilities, or (ii) any violation of or liability or obligation under any Environmental Laws, whether occurring prior to, on or after the Closing and whether accrued, contingent, absolute, determined, determinable, disclosed, undisclosed or otherwise.

1.11 "Escrow Account" means the account established, defined in, and governed by the Environmental Escrow Agreement.

1.12 "Excluded Liabilities" means the liabilities and obligations set forth in the APA and on Annex C to the APA.

1.13 "Financial Claims" means any right or obligation under the APA for or related to the payment, receipt, return, or reimbursement of any portion of the Purchase Price, Working Capital Adjustment, Subordinated Note, Cash/Debt Adjustment, Prorations of taxes or other funds, Additional Payments, Right to Setoff, and Taxes of any kind or form. The Capitalized terms used in this definition of "Financial Claims" shall have the meaning assigned to them in the APA.

1.14 "Governmental or Regulatory Authority" means any court, tribunal, arbitrator, authority, agency, commission, official or other instrumentality exercising governmental or regulatory authority of the United States, any foreign country or any domestic or foreign state, province, county, city, municipality or other political subdivision or any quasi-governmental or regulatory body exercising authority thereunder.

1.15 "Hazardous Materials" means (a) any petroleum or petroleum products, explosives, radioactive materials, asbestos in any form or condition, urea formaldehyde foam insulation and transformers or other equipment that contain dielectric fluid containing regulated levels of polychlorinated biphenyls (PCBs); and (b) any chemicals, materials, wastes, or substances regulated, defined as or included in the definition of "hazardous substances," "hazardous wastes," "extremely hazardous wastes," "restricted hazardous wastes," "toxic substances," "toxic pollutants," "contaminants," or words of similar import under any Environmental Laws as defined herein.

1.16 "Litigation" means the lawsuit filed by Rutherford in New York Supreme Court, Commercial Division, captioned Rutherford Chemicals LLC, Rutherford Chemicals UK Ltd., and Seal Sands Ltd. v. Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland, Inc., Nepcam, Inc., and Cambrex Ltd., Index No. 601176/06, and all claims and counterclaims asserted therein.

1.17 "Loss" or "Losses" shall mean any and all losses, injuries, claims, expenses, damages of any kind, judgments, settlements, debts, penalties, fines, obligations, interest (including prejudgment interest), costs and expenses (including court costs and reasonable attorneys' fees and expenses and reasonable costs of investigation).

3

1.18 "Nepera Facility" means the Rutherford Facility in Harriman, New York as described and defined in the APA. "CasChem Facility" means the Rutherford Facility in Bayonne, New Jersey; "Heico Facility" means the Rutherford Facility in Delaware Water Gap, Pennsylvania; "Zeeland Facility" means the Rutherford Facility in Zeeland, Michigan; and "Seal Sands Facility" means the Rutherford Facility in Middlesborough, England

1.19 "Off-Site" means any area beyond the boundaries or borders of the Real Property of the Rutherford Facilities, as that term "Real Property" is defined in Section 3.12(a) and Schedule 3.12(a) of the APA.

1.20 "Person" means an individual, corporation, partnership, limited liability company, association, trust or other entity or organization, including a governmental or political subdivision or a Governmental or Regulatory Authority.

1.21 "Remediation" means any and all investigation, delineation, cleanup, containment, removal, capping, remediation, corrective action, monitoring or other treatment related to the release, threatened release or presence of Hazardous Materials or any such conduct designed to address any Environmental Liabilities or to comply with any Environmental Laws, including any permit or order under any Environmental Law issued by a Governmental or Regulatory Authority.

1.22 "Remediation Costs" means any and all administrative, legal, investigative, remedial, corrective and other costs, expenses and fees arising from or incurred in connection with any Remediation.

1.23 "Rutherford" means Rutherford Chemicals LLC, , Vertellus Specialties Holdings UK Ltd. (formerly Rutherford Chemicals UK Ltd.), Vertellus Specialties UK Ltd. (formerly Seal Sands Chemicals Ltd.), and Vertellus Specialties Holdings Corp. (formerly known as Rutherford Chemicals Holdings Corp.) and all subsidiaries (except non-wholly owned subsidiaries in China), successors and assigns.

1.24 "Rutherford Facilities" means the five plants, including the real property on which the plants are located, acquired by the Rutherford Acquisition Corp. in the Asset Purchase Agreement defined herein, which include: the Nepera Facility in Harriman, New York; the CasChem facility in Bayonne, New Jersey; the Heico facility in Delaware Water Gap, Pennsylvania; the Zeeland facility in Zeeland, Michigan; and the Seal Sands facility in Middlesborough, England.

1.25 "Third Party Claim" means the assertion by any Person (including, without limitation, any Governmental or Regulatory Authority) who is not a party to this Agreement of any claim or the commencement by any Person of any action or proceeding.

1.26 "Wholly-Owned Affiliate" means, with respect to the Initial Nepera Asset Transferee, any Person that either (i) wholly controls the Initial Nepera Asset Transferee; (ii) is wholly controlled by the Initial Nepera Asset Transferee; or (iii) is wholly controlled by another Person that also wholly controls the Initial Nepera Asset Transferee.

1.27 Any capitalized term in this Agreement that is not specifically defined in

4

Section 1 of this Agreement or in a parenthetical in this Agreement, shall be deemed to have the meaning assigned to such capitalized term in the APA.

ARTICLE II
TERMS

2.1 Settlement Payments and Funding of Escrow. The settlement sum shall be eight million and two hundred and fifty thousand dollars ($8,250,000) (the "Settlement Sum").

2.1.1 Cambrex Payments and Allocation of Settlement Sum.

(a) Cambrex shall pay Rutherford the sum of six hundred thirty-five thousand, nine hundred thirty-nine dollars ($635,939.00), which represents certain Remediation Costs at the Nepera Facility that already have been incurred by Rutherford as of June 30, 2007 ("Past Nepera Expenses"). Cambrex shall pay this amount directly to Rutherford (not to the Escrow Account) within thirty (30) days following the date of this Agreement.

(b) The Settlement Sum minus the Past Nepera Expenses is equal to seven million, six hundred and fourteen thousand, sixty-one dollars ($7,614,061) and shall be referred to herein as the "Escrow Deposit." The Escrow Deposit shall be used for the purposes prescribed in the Environmental Escrow Agreement, which shall include the reimbursement or payment to Rutherford or its designated representatives for any and all Remediation Costs incurred on or after June 30, 2007, resulting from, relating to, or addressing the following: any and all Remediation at the Nepera Facility and the Heico Facility; any and all Remediation of toluene at the Seal Sands Facility; and/or any and all Remediation of mercury at the Zeeland Facility or any other Hazardous Materials at any of the seven closed and inactive lagoons at the Zeeland Facility and the closed Ketone Sludge Pond at the Zeeland Facility formerly used to store a variety of chemicals between the 1950s and the 1970s; provided, however, that no more than one million dollars ($1,000,000) of the Escrow Deposit may be used for the purpose of reimbursing Rutherford for Remediation Costs incurred at sites other than the Nepera Facility.

(c) Cambrex shall deposit into the Escrow Account the amount of the Escrow Deposit minus the amount of Rutherford's Note Payment, as outlined in Paragraph 2.1.2(b) below (the "Net Escrow Deposit"). Cambrex shall deposit the Net Escrow Deposit into the Escrow Account within thirty (30) days following Rutherford's Final Note Payment, as outlined in Section 2.1.2(b) below.

2.1.2 Rutherford Payments. Rutherford shall make the following payments:

(a) After the Closing, Rutherford received tax refunds (the "Tax Refunds") from United Kingdom taxing authorities in the amount of 284,764 British Pounds Sterling for tax year 2002 and 114,938 British Pounds Sterling for tax year 2003. Rutherford shall pay directly to Cambrex (not to the Escrow Account) 399,702 British Pounds Sterling within thirty (30) days following the execution of this Agreement.

(b) Pursuant to the APA, Rutherford provided Cambrex with the Subordinated Promissory Note in the amount of $2,000,000, bearing interest at the rate of 12%

5

per annum. As of September 30, 2007, the outstanding principal and interest on the Subordinated Promissory Note will be three million, one hundred forty-nine thousand, and one hundred eighty-five dollars ($3,149,185). Rutherford shall pay to Cambrex $3,149,185, plus interest accrued on any outstanding amounts from October 1, 2007 until such time as the Note Payments or portions thereof are paid, at the rate of 12% per annum (the "Note Payment"). The Note Payment shall be made by Rutherford by depositing into the Escrow Account the following amounts at the times specified:

(i) Payment 1: one million dollars ($1,000,000) to be deposited into the Escrow Account on or before September 30, 2007;

(ii) Payment 2: one million dollars ($1,000,000) to be deposited into the Escrow Account on or before November 30, 2007; and

(iii) Final Note Payment: the balance of the Note Payment (the "Final Note Payment") to be deposited into the Escrow Account on or before February 28, 2008. The Final Note Payment shall be for one million, one hundred forty-nine thousand, one hundred eighty-five dollars ($1,149,185) plus interest accrued on the outstanding balances of the Note Payment between October 1, 2007 and the date of the Final Note Payment. The interest accrued between the October 1, 2007 and the date of the Final Note Payment shall be at the rate of 12% per annum and shall be determined based on the daily balance of the outstanding Note Payment during that time period.

2.1.3 Notwithstanding the provisions of this Section 2.1, in the event that (i) Vertellus Specialties Holdings Corp. is sold in a stock sale or (ii) all or substantially all of the assets of Vertellus Specialties Holdings Corp. are sold to a buyer not affiliated with Rutherford, the balance of Rutherford's Note Payment still due and owing under Section 2.1.2(b) shall be paid into the Escrow Account within thirty (30) days following the closing date of such sale of Vertellus Specialty Holdings Corp. or substantially all of its assets. Cambrex's Net Escrow Deposit shall then be paid into the Escrow Account within thirty (30) days of Rutherford's payment of the balance of its Note Payment. In the event Rutherford otherwise prepays the full remaining balance of the Note Payment prior to January 28, 2008, Cambrex shall deposit into the Escrow Account the Net Escrow Deposit within thirty (30) days of receipt of notice from Rutherford that it has prepaid the Note Payment. In the event Rutherford prepays the Note Payment prior to September 30, 2007, the total amount of the Note Payment due and owing under Section 2.1.2(b) shall be reduced by the amount of 12% interest per annum, calculated per day, from the date of the prepayment through September 30, 2007. In the event Rutherford fails to make the payments required under Section 2.1.2 of this Agreement, the Parties shall have all of their rights and remedies under the Subordinated Promissory Note, dated November 10, 2003, and attached to the APA.

2.1.4 All payments and deposits required under Section 2.1 shall be made by

6

wire transfer.

2.2 Dismissal of Claims and Counterclaims and Waiver of Certain Rights Under the APA.

2.2.1 The Parties hereby waive and release each other of all Claims and Counterclaims that have been asserted in the Litigation, with the exception of Cambrex's specific assertions in Paragraphs 45 and 47 of the Second Counterclaim of Cambrex's First Amended Answer and Counterclaim ("Second Counterclaim") that Rutherford has breached Section 7.07 (f)(ii) of the APA, which claim Cambrex waives and releases but only to the extent set forth in
Section 2.2.2. This waiver and release shall not be deemed to waive or release any rights or obligations under the APA or otherwise that are specifically preserved or created in this Agreement.

2.2.2 Upon execution of this Agreement, within ten (10) days:

(a) the Parties shall jointly file a motion seeking dismissal with prejudice of all Claims and Counterclaims that have been asserted in the Litigation, with the exception of Cambrex's specific assertions in Paragraphs 45 and 47 of its Second Counterclaim that Rutherford has breached Section 7.07(f)(ii) of the APA, which Cambrex shall dismiss without prejudice; provided however that Cambrex waives any right to seek the recovery of any damages or costs that it may have suffered or incurred prior to the date of this Agreement that did result or might have resulted from any alleged breach or violation of
Section 7.07(f)(ii) of the APA.

(b) Cambrex shall file notice of dismissal with prejudice of its appeal to the Appellate Division, First Department, of the Supreme Court of the State of New York concerning the March 27, 2007 Decision and Order of the trial court in the Litigation; and

(c) the Parties shall jointly file a stipulation and proposed order to release the bond that Cambrex has posted in connection with the order preliminarily enjoining Rutherford from demolishing the Nepera Facility.

2.2.3 All Parties hereby waive and extinguish all rights under the APA or otherwise to seek indemnification, damages, injunctive relief, declaratory relief, or any other remedy for breach of any warranty, covenant, representation, Assumed Liability, Excluded Liability, or other obligation contained in the APA, as they relate to any or all Financial Claims, whether ripe, accrued, unaccrued, known or unknown at the time of the execution of this Agreement.

2.2.4 All Parties hereby waive and extinguish all rights under the APA to seek indemnification, damages, injunctive relief, declaratory relief, or any other remedy for breach of any warranty, covenant, representation, Assumed Liability, Excluded Liability or other obligation contained in the APA as they relate to Environmental Liabilities, including any and all Remediation related thereto, EXCEPT with respect to the Parties' rights and obligations as set forth in Subparagraphs 2.3.1(a)(i)-(v) of this Agreement.

7

2.2.5 Rutherford hereby waives any right to seek redress from Cambrex for future remediation of the toluene plume at Seal Sands even if such remediation is to occur Off-Site; except that nothing herein shall be construed to restrict or prohibit Rutherford from utilizing the Escrow Account to pay for remediation of or associated with the toluene plume at Seal Sands, including Off-Site, up to the limits provided for in Section 2.1.1(b).

2.2.6 All Claims and Counterclaims dismissed or waived under the terms of this Agreement are so dismissed or waived by the Parties, which shall include for these purposes their respective affiliates, parents, subsidiaries, present and former officers, directors, partners, employees, agents, attorneys, insurers, administrators, receivers, trustees, conservators, predecessors, successors and assigns.

2.3 Amendment and Modification of the APA.

2.3.1. The APA is amended and modified as follows:

(a) Any and all rights, obligations and limitations of the Parties under the APA with respect to Environmental Liabilities and the Remediation thereof at the Rutherford Facilities, including but not limited to the covenants made in Sections 6.03, 6.04, 7.08 and 7.11 of the APA and all rights, obligations and limitations related thereto, and all rights, obligations, limitations and liabilities related to Environmental Liabilities at or relating to the Rutherford Facilities that are denoted in the APA as Assumed Liabilities or Excluded Liabilities, are extinguished and hereby governed by the terms of this Agreement, INCLUDING AS FOLLOWS:

(i) Cambrex shall be solely responsible for Environmental Liabilities attributable to or arising from the pre-Closing Off-Site treatment, storage, transportation, release, threatened release, disposal or arrangement for disposal of any Hazardous Materials by or on behalf of Cambrex or any of their respective predecessors or affiliates or otherwise in connection with any of the Rutherford Facilities; provided, however, that Cambrex shall have no responsibility for the Remediation of Hazardous Materials on, in, or below the Real Property even if such Remediation arises from, relates to, or is required to remedy Off-Site Environmental Liabilities unless such Remediation is otherwise part of Cambrex's responsibilities or obligations under this Agreement, including but not limited to the other subparagraphs of this Section 2.3.1(a); provided further, that Cambrex shall have no responsibility for Remediation or any fines or penalties attributable to or arising from the Off-Site release or threatened release of toluene from the toluene plume at the Seal Sands Facility.

(ii) Cambrex shall be solely responsible for (1) any Third Party Claims for damage or injury suffered as the result of products sold in connection with the operation of the Rutherford Facilities prior to the Closing; and (2) any Third Party Claims for any personal injuries, property damage (other than damage to the real property of the Rutherford Facilities) or natural resource damages attributable to or arising from any pre-Closing exposure to or damage from any Hazardous Materials with respect to the Rutherford Facilities.

(iii) Cambrex shall conduct and complete all Remediation required at the CasChem facility under the New Jersey Industrial Site Recovery Act, as amended,

8

and the regulations thereunder ("ISRA"), pursuant to and as fully set forth in
Section 7.07 of the APA.

(iv) Cambrex shall conduct and complete all Remediation of Hazardous Materials in, on, beneath, from, or adjacent to the Nepera Facility required to be implemented by the New York Department of Environmental Conservation ("NYSDEC") pursuant to the Record of Decision for Site No. 33606, dated March 1997 (the "ROD"), pursuant to and as fully set forth in Section 7.07 of the APA.

(v) All rights and obligations set forth in Section 7.07 of the APA, including those applicable to both Seller and Buyer, shall be fully applicable and shall be enforceable pursuant to and in accordance with the terms of this Agreement, but only to the extent such rights and obligations relate to performance of Remediation at the CasChem Facility under ISRA or Remediation at the Nepera Facility under the ROD, except that all rights and obligations under
Section 7.07(f)(i) and Section 7.07(g)(iv) are hereby waived and extinguished.

(b) Any disputes regarding or relating to the application of the APA, including but not limited to any claims for breach, enforcement, indemnification, interpretation or damages under the APA, shall be submitted, processed, adjudicated and resolved in accordance with the terms of Section 4.1 below.

2.3.2 To the extent any terms of this Agreement and the APA are deemed to conflict or to be inconsistent, the terms of this Agreement shall govern and shall be applied.

2.4 Indemnity.

2.4.1 Cambrex shall, jointly and severally, to the fullest extent permitted by applicable law, indemnify, defend and hold harmless Rutherford from and against any Losses resulting from any Environmental Liabilities suffered or incurred by Rutherford for which Cambrex is responsible under Section 2.3.1(a)(i)-(v). Except with respect to Cambrex's obligations that are specifically preserved or otherwise set forth in this Agreement, including those set forth in Section 2.3.1(a)(i)-(v), Rutherford shall, jointly and severally, to the fullest extent permitted by applicable law, indemnify, defend and hold harmless Cambrex from and against any Losses resulting from any Environmental Liabilities suffered or incurred by Cambrex arising out of, resulting from or relating to (x) the presence of Hazardous Materials at any of the Rutherford Facilities or (y) Remediation, fines or penalties relating to any Off-Site release or threatened release of toluene from the toluene plume at the Seal Sands Facility.

2.4.2 If Cambrex shall receive notice or otherwise learn of a Third Party Claim with respect to which Rutherford is obligated to provide indemnification pursuant to Section 2.4.1 including without limitation any Third Party Claim brought under any Environmental Laws, Cambrex shall give Rutherford written notice thereof promptly after becoming aware of such Third Party Claim; provided, however, that the failure of Cambrex to give notice as provided in this provision shall not relieve Rutherford of its obligations under Section 2.4 except to the extent that Rutherford is prejudiced by such failure to give notice. Such notice shall describe the Third Party Claim in reasonable detail and, if ascertainable, shall indicate the amount (estimated if necessary) of the Loss that has been or may be sustained by Cambrex.

9

2.4.3 Rutherford may elect to defend or seek to settle or compromise, at Rutherford's own expense and by Rutherford's own counsel, any Third Party Claim. Within thirty (30) days after the receipt of notice from Cambrex in accordance with Section 2.4.2 (or sooner, if the nature of such Third Party Claim so requires), Rutherford shall notify Cambrex whether Rutherford will assume responsibility for defending such Third Party Claim. After notice from Rutherford to Cambrex of its election to assume the defense of a Third Party Claim, Rutherford shall not be liable to Cambrex under this Section 2.4 for any legal or other expenses (except expenses approved in advance by Rutherford ) incurred by Cambrex in connection with the defense thereof; provided that if the defendants in any such claim include both Rutherford and Cambrex and, in Cambrex's reasonable judgment, a conflict of interest between Rutherford and Cambrex exists in respect of such claim, Cambrex shall have the right to employ separate counsel to represent itself at its own expense. If Rutherford elects not to assume responsibility for defending a Third Party Claim, or fails to notify Cambrex of its election as provided in this Section 2.4.3, Cambrex may defend or (subject to the remainder of this Section 2.4) seek to compromise or settle such Third Party Claim and seek redress from Rutherford under the terms of this Agreement.

2.4.4 If Rutherford chooses to defend or to seek to compromise or settle any Third Party Claim, Cambrex shall make available to Rutherford any personnel or any books, records or other documents within Cambrex's control or which it otherwise has the ability to make available that are necessary or appropriate for such defense, settlement or compromise, and shall otherwise cooperate in the defense, settlement or compromise of such Third Party Claim.

2.4.5 In the event of payment by Rutherford to Cambrex in connection with any Third Party Claim that Cambrex is not responsible for under the terms of this Agreement, Rutherford shall, to the fullest extent permitted by applicable law, be subrogated to and shall stand in the place of Cambrex as to any events or circumstances in respect of which Cambrex may have any right or claim relating to such Third Party Claim against any claimant or plaintiff asserting such Third Party Claim or against any other Person. Cambrex shall cooperate with Rutherford in a reasonable manner, and at the cost and expense of Rutherford, in prosecuting any subrogated right or claim.

2.4.6 Other Procedures for Indemnification. Any claim for indemnification by Cambrex under Section 2.4 which does not result from a Third Party Claim shall be asserted by written notice given by Cambrex to Rutherford. Rutherford shall have a period of twenty (20) days after the receipt of such notice within which to respond thereto. If Rutherford does not respond within such twenty (20) day period, Rutherford shall be deemed to have refused to accept responsibility to make payment. If Rutherford does not respond within such twenty (20) day period or rejects such claim in whole or in part, Cambrex shall be free to pursue such remedies as may be available to such party under this Agreement.

2.4.7 Indemnification Procedures Apply Equally to Rutherford and Cambrex.

In the event Rutherford receives notice of a Third Party Claim described or covered in Section 2.3.1 (a)(ii) or receives notice of a claim relating to Off Site Hazardous Materials described or covered in Section 2.3.1(a)(i), Rutherford and Cambrex shall follow and adhere to the provisions of
Section 2.4.2, 2.4.3, 2.4.4, 2.4.5 and 2.4.6, EXCEPT THAT the rights and

10

obligations set forth for Cambrex in each of these Sections shall apply to Rutherford and the rights and obligations set forth for Rutherford in each of these Sections shall apply to Cambrex.

2.4.8 Notice of Remediation Activities at Nepera.

(a) Until the earlier of such time as (i) Cambrex receives a "no further action" letter or its equivalent from the New York State Department of Environmental Conservation ("NYSDEC") or such other Governmental or Regulatory Authority that Cambrex has completed all required Remediation of Hazardous Materials at the Nepera Facility pursuant to the ROD or (ii) Rutherford receives a "no further action" letter or its equivalent from a Governmental or Regulatory Authority that all Remediation at the Nepera Facility required under the RCRA RFI corrective action process has been completed as required by applicable law, Cambrex shall have the right to receive copies of material reports, work plans, agreements or letters submitted by Rutherford to a Governmental or Regulatory Authority and other material documents that relate to Remediation at the Nepera Facility at the same time as such reports, plans, agreements or documents are submitted to the Governmental or Regulatory Authority, and shall receive prior notice of and attend any meetings (as an observer) with such Governmental or Regulatory Authorities; provided that the Parties recognize that ultimate decision-making authority with respect to such Remediation (other than Remediation pursuant to the ROD) is retained by Rutherford.

(b) Until such time as Cambrex receives a "no further action" letter or its equivalent from NYSDEC or such other Governmental or Regulatory Authority that Cambrex has completed all required Remediation of Hazardous Materials at the Nepera Facility pursuant to the ROD, Rutherford shall have the right to receive copies of any material reports, work plans, agreements or letters submitted by Cambrex to a Governmental or Regulatory Authority, and other material documents that relate to Remediation under the ROD at the Nepera Facility at the same time as such reports, plans, agreements or documents are submitted to the Governmental or Regulatory Authority, and shall receive prior notice of and attend any meetings (as an observer) with such Governmental or Regulatory Authorities; provided that the Parties recognize that ultimate decision-making authority with respect to such Remediation under the ROD is retained by Cambrex.

(c) Rutherford shall not, without first providing reasonable prior notice to, and obtaining the express written consent of, Cambrex, communicate with the NYSDEC or any other Governmental or Regulatory Authority or any third Person regarding Remediation of Hazardous Materials at the Nepera Facility pursuant to the ROD, and Rutherford shall facilitate the participation of Cambrex in all such communications. Cambrex shall not, without first providing reasonable prior notice to, and obtaining the express written consent of, Rutherford, communicate with the NYSDEC or any other Governmental or Regulatory Authority or any third Person regarding Remediation of Hazardous Materials at the Nepera Facility pursuant to the RCRA RFI corrective action process or Remediation that is otherwise not Cambrex's responsibility under
Section 2.3.1(a)(iv) hereof, and Cambrex shall facilitate the participation of Rutherford in all such communications.

11

2.4.9 Notice of Remediation Activities at CasChem.

(a) Until such time as Cambrex receives a "no further action" letter or its equivalent from the New Jersey Department of Environmental Protection ("NJDEP") or any other Governmental or Regulatory Authority with jurisdiction over the CasChem Facility that Cambrex has completed all required Remediation of Hazardous Materials at the CasChem Facility pursuant to ISRA, Cambrex shall have the right to receive copies of material reports, work plans, agreements submitted by Rutherford to a Governmental or Regulatory Authority, and other material documents that relate to Remediation at the CasChem Facility at the same time as such reports, plans, agreements or documents are submitted to the Governmental or Regulatory Authority, and shall receive prior notice of and attend any meetings (as an observer) with such Governmental or Regulatory Authorities; provided that the Parties recognize that ultimate decision-making authority with respect to such Remediation (other than Remediation pursuant to ISRA) is retained by Rutherford.

(b) Until such time as Cambrex receives a "no further action" letter or its equivalent from the NJDEP or any other Governmental or Regulatory Authority with jurisdiction over the CasChem Facility that Cambrex has completed all required Remediation of Hazardous Materials at the CasChem Facility pursuant to ISRA, Rutherford shall have the right to receive copies of any material reports, work plans, agreements submitted by Cambrex to a Governmental or Regulatory Authority, and other material documents that relate to Remediation at the CasChem Facility at the same time as such reports, plans, agreements or documents are submitted to the Governmental or Regulatory Authority, and shall receive prior notice of and attend any meetings (as an observer) with such Governmental or Regulatory Authorities; provided that the Parties recognize that ultimate decision-making authority with respect to such Remediation pursuant to ISRA is retained by Cambrex.

(c) Rutherford shall not, without first providing reasonable prior notice to, and obtaining the express written consent of, Cambrex, communicate with the NJDEP or any other Governmental or Regulatory Authority or any third Person regarding Remediation of Hazardous Materials at the CasChem Facility pursuant to ISRA, and Rutherford shall facilitate the participation of Cambrex in all such communications. Cambrex shall not, without first providing reasonable prior notice to, and obtaining the express written consent of, Rutherford, communicate with the NJDEP or any other Governmental or Regulatory Authority or any third Person regarding Remediation of Hazardous Materials at the CasChem Facility that is not Cambrex's responsibility under Section 2.3.1(a)(iii) hereof, and Cambrex shall facilitate the participation of Rutherford in all such communications.

2.4.9 Remedies Cumulative. The remedies provided in this Section 2.4 shall be cumulative and shall not preclude the assertion by any Party of any other rights or the request for any and all other remedies, to the extent permitted by this Agreement.

2.5 Sale and Assignability.

2.5.1 This Agreement shall be binding upon the Parties hereto, their successors, subsidiaries (except non-wholly owned subsidiaries in China), assigns, agents, directors, officers and employees, provided that no Party may assign, delegate or otherwise transfer any of its rights

12

or obligations under this Agreement or the APA without the consent of the other Parties hereto. Notwithstanding the foregoing, Rutherford may transfer or assign in whole or in part its rights and obligations under this Agreement to: (i) one or more of its subsidiaries or affiliates; (ii) any financial institution providing purchase money or other financing to Rutherford or to one or more of its subsidiaries or affiliates; (iii) a purchaser of all or a substantial portion of the assets of the Rutherford Chemicals Business; or (iv) a purchaser of all or a substantial portion of the assets of Nepera, but no such transfer or assignment shall relieve Rutherford of any of its obligations hereunder. In the case of a sale of all or a substantial portion of the assets of the Rutherford Chemicals Business, the transferee shall assume the related obligations of Rutherford hereunder and, in the case of the sale of all or a substantial portion of the assets of Nepera, only the Person that purchases all or a substantial portion of the assets of the Nepera Facility directly from Rutherford (the "Initial Nepera Asset Transferee") shall assume the related obligations of Rutherford hereunder as they apply to the Nepera Facility. The Initial Nepera Asset Transferee shall have no obligation to bind future transferees to the terms of this Agreement; provided, however, that in the event the Initial Nepera Asset Transferee sells or transfers all or a substantial portion of the assets of Nepera to a Wholly-Owned Affiliate, such Wholly-Owned Affiliate shall assume the related obligations of Rutherford hereunder as they apply to the Nepera Facility. Such obligations shall survive until the earlier of: (i) thirty (30) months after the Initial Nepera Asset Transfer directly from Rutherford; or (ii) when all remedial construction required as part of the RCRA RFI corrective action process is complete or the Nepera Facility receives a "Completion Notice" from the jurisdictional Governmental or Regulatory Authorities (such as a "no further action" letter or its equivalent or acceptance by such Governmental or Regulatory Authority of Rutherford's final notice of completion). For purposes of this Section 2.5.1, the Initial Nepera Asset Transferee shall not include any entity that is an Affiliate of Rutherford. Rutherford hereby represents that it will maintain sufficient assets to fulfill its obligations under this Agreement in the event of a sale of assets of the Rutherford Chemicals Business that are material to the overall financial condition of Rutherford or the sale of a Rutherford Facility by Rutherford.

2.5.2 If Rutherford enters into any agreement to sell all or a substantial portion of a Rutherford Facility, Rutherford shall provide Cambrex with notice of such transaction within 48 hours of closing and shall disclose all material terms relating to any assumption by the transferee of any of Rutherford's obligations under this Settlement Agreement.

ARTICLE III
INTERPRETATIVE MATTERS

3.1 Interpretation of Agreement.

3.1.1 The Agreement will be interpreted and enforced under the laws of the State of New York, without regard to principles of choice of law.

3.1.2 The Parties agree that this Agreement and the negotiations relating thereto do not constitute an admission or evidence of any wrongdoing, misconduct or violation of any law whatsoever by either Party and further agree that neither this Agreement nor the negotiations thereto shall be admissible in evidence in any proceeding except to enforce its terms.

13

3.1.3 This Agreement, together with the documents specifically referenced herein, set forth the entire agreement and understanding among the Parties with respect to the transaction, agreements and understandings relating to the subject matter hereof. No representations, promises or inducements have been made by the Parties which are not embodied in this Agreement, together with the documents specifically referenced herein, and none of the Parties hereto shall be bound by or liable for the alleged representation, promise, inducement or statement of intent not so set forth.

3.1.4 This Agreement may not be altered, amended, abandoned, modified, waived, superseded, canceled or discharged, except by a further writing subscribed to by all Parties.

3.1.5 This Agreement may be executed in counterparts, all of which counterparts shall constitute one agreement, and the Parties agree that a facsimile signature shall be binding.

3.1.6 All notices, requests, claims, demands and other communications to any party hereunder must be in writing and must be given by hand delivery, by courier service or by facsimile to the applicable party at the following address:

if to Cambrex, to:

Cambrex Corporation

One Meadowlands Plaza
East Rutherford, New Jersey 07073 Attention: General Counsel

with a copy to:

Milbank, Tweed, Hadley & McCloy LLP One Chase Manhattan Plaza New York, New York 10005
Attention: Thomas A. Arena, Esq.

if to Rutherford, to:

Vertellus Specialties Inc.
300 North Meridian Street, Suite 1500
Indianapolis, Indiana 46204

Attention: General Counsel

with a copy to:

Akin Gump Strauss Hauer & Feld LLP 1333 New Hampshire Avenue, NW Washington, DC 20036
Attention: Perry M. Rosen, Esq.

14

ARTICLE IV
ENFORCEMENT OF THIS AGREEMENT AND THE APA

4.1 Enforcement of this Agreement and the APA.

4.1.1 Any claim arising out of or relating to this Agreement, or the subject matter thereof, including any claim for breach, enforcement, indemnification or damages under this Agreement, and any future claims arising out of, relating to, or regarding breach, enforcement, indemnification or damages under the APA, as amended and modified herein, will be resolved solely and exclusively through dispute resolution conducted in accordance with the procedures and rules of the International Institute of Conflict Prevention and Resolution ("CPR") Rules for Non-Administered Arbitration then in effect; except that pursuant to Section 13.2 of the CPR Rules for Non-Administered Arbitration, a Party may seek interim measures and/or provisional relief from a court in order to protect its rights under this Agreement or the APA. The process for dispute resolution is prescribed as follows, to the extent such procedures differ from those set forth in the CPR Rules for Non-Administered Arbitration:

(a) If, in the opinion of one of the Parties, there is a dispute between Rutherford and Cambrex with respect to the interpretation or implementation of this Agreement, the opining Party shall send a written Notice of Dispute to the other party which outlines the nature of the dispute and requests informal negotiations to resolve the dispute. Such period of informal negotiations shall not extend beyond twenty (20) days from the date when the Notice of Dispute was received unless the period is extended by written agreement of the Parties. After initiation of the informal negotiation period, any Party to the dispute may, upon seven (7) days' prior written notice to the other Party, terminate the informal negotiations.

(b) If informal negotiations are unsuccessful or are terminated in accordance with Subparagraph (a), a Party may initiate arbitration by sending, via certified mail, a written notice of the claim to the other Party that (i) identifies and describes the nature of each claim asserted, (ii) the facts upon which each claim is based, and (iii) the relief or remedy sought. The Party initiating arbitration shall notify CPR that a demand for arbitration has been made and the Parties shall endeavor to agree on the appointment of a single arbitrator. If the Parties have not agreed on a mutually satisfactory arbitrator within fifteen (15) days of the written notice of the claim, the CPR shall forthwith appoint an arbitrator pursuant to CPR Rule 5.4.

(c) Within thirty (30) days of receiving a written notice of claim for arbitration, the responding Party may file an answering statement setting forth a response to the claim and the issues presented. The filing of the answering statement shall in no way limit the responding Party's right to assert other defenses or to assert timely counterclaims or take other positions that may become apparent during the course of the arbitration.

(d) The arbitrator will promptly set a hearing date and time, taking into account the Parties' need to take discovery reasonably necessary for the prosecution or defense of any claim, and will mail written notice of the hearing date to each of the Parties at least sixty (60) days in advance, unless the Parties otherwise agree or mutually waive notice.

15

(e) The arbitration shall be held in New York City and the laws of the State of New York shall apply, without resort to choice of law principles.

(f) The arbitrator is empowered to subpoena witnesses and compel the production of documents to the extent permitted in a judicial proceeding, upon his or her own initiative or the request of one of the Parties. The arbitrator may grant injunctions or other relief in such dispute, but may not award punitive or exemplary damages, unless such limitation is prohibited by law.

(g) No later than fifteen (15) days before the arbitration, the Parties will exchange lists of witnesses, including any experts, and copies of all exhibits intended to be used at the arbitration. Each party shall have the right to subpoena witnesses and documents for the arbitration, as well as documents relevant to the case from third parties.

(h) The arbitrator shall have the authority to entertain a motion to dismiss or a motion for summary judgment by any Party and shall apply the standards governing such motions under the New York CPLR.

(i) The award of the arbitrator shall be FINAL AND BINDING on the Parties and may be enforced by any court of competent jurisdiction and may be executed against the person and assets of the losing Party in any jurisdiction.

4.1.2 No claim for damages may be made for breach of this Agreement or for breach of any surviving portion of the APA unless the value of such claim exceeds $75,000. The arbitrator shall immediately dismiss any claim submitted for arbitration where the complaining party can not establish that the value of its claim will exceed $75,000; provided, however, that this provision shall not apply to a claim or a motion by a Party for interim measures, provisional relief or injunctive relief as permitted under this Agreement.

IN WITNESS WHEREOF, the Parties to this Agreement have caused this Agreement to be duly executed by their respective authorized officers as of the day and year first written above.

RUTHERFORD CHEMICALS LLC,
VERTELLUS SPECIALTIES HOLDINGS CORP.

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

VERTELLUS SPECIALTIES UK LTD., AND
VERTELLUS SPECIALTIES HOLDINGS UK LTD.

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

16

CAMBREX CORPORATION

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

NEPERA, INC., CASCHEM, INC.,
ZEELAND CHEMICALS, INC., NEPCAM, INC.

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

CAMBREX LIMITED

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

17

ENVIRONMENTAL ESCROW AGREEMENT

This ENVIRONMENTAL ESCROW AGREEMENT ("Environmental Escrow Agreement") is made and entered into as of July 30, 2007, by and between Rutherford Chemicals LLC, Vertellus Specialties Holdings UK Ltd. (formerly Rutherford Chemicals UK Ltd.), Vertellus Specialties UK Ltd. (formerly Seal Sands Chemicals Ltd.), and Vertellus Specialties Holdings Corp. (formerly Rutherford Chemicals Holdings Corp.) (collectively referred to herein as "Rutherford"), and Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland Chemicals, Inc. (a/k/a Zeeland, Inc.), Nepcam, Inc., and Cambrex Ltd. (collectively referred to herein as "Cambrex"), as each of these parties is defined in the Settlement Agreement, and the Wells Fargo Bank, National Association, as escrow agent (the "Escrow Agent").

RECITALS:

A. Rutherford and Cambrex are among the parties to a settlement agreement, dated as of July 30, 2007 (the "Settlement Agreement"), pursuant to which the Parties have agreed to settle all Claims and Counterclaims in the Litigation as defined in the Settlement Agreement.

B. Pursuant to the terms of the Settlement Agreement, Cambrex and Rutherford have agreed to deposit into Escrow seven million, six hundred fourteen thousand and sixty-one dollars ($7,614,061) to be used to reimburse Rutherford for Qualified Expenses (as defined below) incurred by Rutherford in connection with Rutherford's performance of certain Remediation to be undertaken at certain of the Rutherford Facilities, as set forth more fully below.

C. Upon Termination of the Environmental Escrow Agreement as defined herein, the Escrow Funds held by the Escrow Agent in the Escrow Account, if any, will be disbursed to Rutherford pursuant to the terms of this Agreement.

AGREEMENTS:

NOW, THEREFORE, in consideration of the covenants set forth in this Environmental Escrow Agreement, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Rutherford, Cambrex and the Escrow Agent hereby agree as follows:

ARTICLE I
ESCROW

1.1 Defined Terms. Capitalized terms used in this Environmental Escrow Agreement but not defined herein shall have the meaning ascribed to them in the Settlement Agreement.

(a) The term "Settlement Agreement" as used herein, means the Settlement Agreement and Release executed by the same parties in conjunction with this Environmental Escrow Agreement and to which this Environmental Escrow Agreement has been made an Exhibit. The Settlement Agreement is attached hereto as Exhibit A.

(b) The term "Remediation" shall have the meaning ascribed to it in the Settlement Agreement. The term "Remediation Work" shall mean any work performed to

18

investigate, conduct, manage, carry out or complete Remediation.

(c) The term "Permitted Investments" means:

i. direct obligations of, or obligations the principal of and interest on which are unconditionally guaranteed by, the United States of America (or by any agency thereof to the extent such obligations are backed by the full faith and credit of the United States of America) and rated at least investment grade, in each case maturing within one year from the date of acquisition thereof;

ii. investments in commercial paper maturing within 180 days from the date of acquisition thereof and rated, at such date of acquisition, A-1 or better by Standard & Poor's Ratings Services or P-1 or better by Moody's Investors Service, Inc.; or

iii. investments in certificates of deposit, banker's acceptances and time deposits maturing within 180 days from the date of acquisition thereof issued or guaranteed by or placed with, and money market deposit accounts issued or offered by, any domestic office of any commercial bank organized under the laws of the United States of America or any State thereof which has a combined capital and surplus and undivided profits of not less than $250,000,000.

1.2 Appointment of the Escrow Agent. Cambrex and Rutherford hereby appoint Wells Fargo Bank, National Association, as the Escrow Agent, and the Escrow Agent hereby agrees to assume and perform the duties of the Escrow Agent under and pursuant to this Agreement.

1.3 Deposit of Escrow Amount.

1.3.1 Rutherford shall deliver to the Escrow Agent the amount equal to Rutherford's Note Payment pursuant to Section 2.1.2(b) of the Settlement Agreement, or in the event of a sale of Vertellus Specialties Holding Corp., Rutherford's deposit shall be made pursuant to Section 2.1.3 of the Settlement Agreement. Upon delivery of the full amount of the Note Payment to the Escrow Agent, and pursuant to Section 2.1.1(b) of the Settlement Agreement, Cambrex shall deliver to the Escrow Agent the amount of the Escrow Deposit minus the amount of Rutherford's Note Payment ("Net Escrow Deposit"). Both the Net Escrow Deposit and the Note Payment shall be delivered to the Escrow Agent in accordance with the schedule of payments set forth in Section 2.1 of the Settlement Agreement. All such deposits (collectively referred to herein as the "Environmental Deposit") shall be made via wire transfer of immediately available funds to the following account maintained by the Escrow Agent:

Bank: Wells Fargo Bank, National Association Location: Indianapolis, Indiana
Account Number: TBD
ABA Number: 121-000-248 Reference: Rutherford Vertellus Environmental Escrow Attention: John D. Alexander

1.3.2 The Escrow Agent shall invest the Environmental Deposit in an interest-

19

bearing account ("Escrow Account") by no later than the close of business on the business day next following the day on which the Environmental Deposit is received. In the absence of other written investment instructions, the Environmental Deposit shall be invested in a Wells Fargo Bank Money Market Deposit Account (the "MMDA"). The Parties understand that amounts on deposit in the MMDA are insured, subject to the applicable rules and regulations of the Federal Deposit Insurance Corporation (FDIC), in the basic FDIC insurance amount of $100,000 per depositor, per insured bank. This includes principal and accrued interest up to a total of $100,000. The Parties understand that deposits in the MMDA are not secured. All reasonable administrative costs, fees and expenses of the Escrow Agent related to such account (collectively, "Fees") may be deducted by the Escrow Agent from the Escrow Account.

1.3.3 All Permitted Investments shall be considered part of the Escrow Account. In determining whether and how much of the Escrow Account to deposit or hold in Permitted Investments, the Escrow Agent shall ensure that there are sufficient funds available to pay Qualified Expenses within the time periods set forth in 1.4.5 of this Escrow Agreement.

1.4 Distribution of the Escrow Account.

1.4.1 Qualified Expenses. For purposes of this Environmental Escrow Agreement, "Qualified Expenses" means costs incurred on or after July 1, 2007 by Rutherford or any of its successors, assigns, contractors, agents, employees or representatives relating to or in connection with Remediation at the five Rutherford Facilities as follows: any and all Remediation at the Nepera facility and the Heico Facility; any or all Remediation of toluene at the Seal Sands Facility; and/or any and all Remediation of mercury at the Zeeland Facility or any Hazardous Materials at any of the seven closed and inactive lagoons at the Zeeland Facility and the closed Ketone Sludge Pond at the Zeeland Facility formerly used to store a variety of chemicals between the 1950s and the 1970s. Qualified Expenses shall include, without limitation, all costs and expenses related to the management of the work by Rutherford, attorneys' fees for legal services rendered in connection with Remediation as described herein, and costs and expenses related to community relations and outreach to the community to the extent such costs and expenses relate to Remediation as described herein; provided that any such Remediation Work has been performed in accordance with the standards set forth in Section 1.4.3 of this Environmental Escrow Agreement; provided further that not more than one million dollars ($1,000,000) may be used for the purpose of paying Rutherford or its designated Representatives for Qualified Expenses relating to Remediation at the Zeeland, Seal Sands or Heico Facilities combined and provided further that any costs incurred by Rutherford with respect to the Remediation Work shall not be considered "Qualified Expenses" for the purposes of this Environmental Escrow Agreement if such costs relate to actions taken following the issuance of a "no further action" letter, certificate of completion, or equivalent notice from a Governmental or Regulatory Authority issued on or after the date of the execution of this Agreement, reflecting that the respective Remediation Work to which the incurred costs related has been completed.

1.4.2 Cessation or Modification of Remediation Work. Rutherford shall deliver to Cambrex and the Escrow Agent (a) any order of, or agreement with, any Governmental or Regulatory Authority in respect of which Rutherford might make a claim for a distribution hereunder, as well as any modifications or amendments of or supplements to existing

20

orders or agreements, as promptly as practicable following the issuance or execution thereof and (b) any "no further action" letter, certificate of completion or equivalent document issued with respect to any aspect of, or all, the Remediation Work as promptly as practicable following the issuance thereof.

1.4.3 Remediation Work Standards. In order for an expense to be deemed a Qualified Expense, such expense shall be incurred in connection with Remediation Work which (a) is conducted in accordance with applicable Environmental Laws and (b) unless required by a Governmental or Regulatory Authority, is (i) technically feasible and practicable and (ii) based on customary and accepted engineering practices.

1.4.4 Claims by Rutherford. From time to time during the term of this Environmental Escrow Agreement, Rutherford or any of its successors, assigns, contractors, agents, employees or representatives (collectively "Representatives") authorized by Rutherford to act on its behalf may submit to the Escrow Agent, with copy to Cambrex, a certificate substantially in the form of Exhibit B (a "Certificate of Instruction"), setting forth the amount of expenses incurred by Rutherford or its Representatives (the "Owed Amount") which Rutherford or its Representatives believes to be Qualified Expenses. Each such Certificate of Instruction shall describe such expenses in reasonable detail and be accompanied by receipts, invoices and other appropriate and customary documentation sufficient to demonstrate the amount of such expenses and to support Rutherford's claim that such expenses are Qualified Expenses.

1.4.5 Objections and Payment. Cambrex shall have fifteen (15) calendar days from the date it receives the Certificate of Instruction to provide the Escrow Agent and Rutherford with written notice objecting to such Certificate or any portion thereof ("Objection Period"). If the Escrow Agent has not received from Cambrex a certificate in substantially the form of Exhibit C attached hereto (an "Objection Certificate") within the Objection Period, the Escrow Agent shall deliver to Rutherford within seven (7) calendar days following the expiration of the Objection Period the portion of the Escrow Account equal to the dollar amount of the Qualified Expenses set forth in the Certificate of Instruction, up to an aggregate amount equal to the Escrow Account (less any fees). If the Escrow Agent and Rutherford each receive an Objection Certificate from Cambrex objecting to the Certificate of Instruction or any portion thereof, the Escrow Agent shall (i) deliver to Rutherford within such seven calendar day period the amount of Qualified Expenses that is not in dispute and (ii) retain the amount disputed pending resolution of the dispute as follows:

(a) Rutherford and Cambrex shall use their commercially reasonable efforts to resolve Cambrex's objection by mutual agreement, in which case Rutherford and Cambrex shall provide the Escrow Agent with a certificate substantially in the form of Exhibit D attached hereto (a "Resolution Certificate") stating that Rutherford and Cambrex have agreed that the Owed Amount referred to in such Certificate of Instruction (or a specified portion thereof) is payable to Rutherford, so long as sufficient funds are on deposit in the Escrow Account to make such payment.

(b) If Rutherford and Cambrex cannot mutually resolve Cambrex's objection within thirty (30) days after the expiration of the Objection Period, then Cambrex shall submit the dispute to the Special Master, who shall make a determination within thirty (30) days

21

as to whether the Owed Amount, or any portion thereof, constitutes a Qualified Expense. The Special Master shall base any such determination on whether the expenses constituting the Owed Amount are costs relating to or associated with a Qualified Expense as defined in Section 1.4.1 of this Agreement. The decision of the Special Master shall be final and binding upon the Parties.

(c) In the event Cambrex submits or makes any objection under any provision of this Environmental Escrow Agreement or other challenge to Rutherford's submission for payment from the Escrow Account or request for Termination of the Environmental Escrow Agreement under Paragraph 1.6 of this Agreement, and that objection or challenge is resolved by the Special Master in Rutherford's favor in whole or in part, Cambrex shall pay to Rutherford, within ten (10) days after resolution of the matter by the Special Master: (i) all fees and costs incurred by Rutherford in responding to and addressing that part of Cambrex's objection or challenge that was resolved in Rutherford's favor, including but not limited to all consultant's and attorneys' fees and the reasonable hourly fee for employee time used to address such objection or challenge; and (ii) all fees and costs of the Special Master associated with addressing and adjudicating that part of Cambrex's objection or challenge that was resolved in Rutherford's favor. Failure of Cambrex to make a payment of fees and costs required under this paragraph shall forfeit and extinguish Cambrex's right to make future objections or challenges to Rutherford's submission of any claim for reimbursement from the Escrow Account.

(d) In the event that Cambrex submits or makes any objection under any provision of this Environmental Escrow Agreement or other challenge to Rutherford's submission for payment from the Escrow Account or request for Termination of the Environmental Escrow Agreement under Paragraph 1.6 of this Agreement, and that objection or challenge is resolved by the Special Master in Cambrex's favor in whole or in part, Rutherford shall pay Cambrex, within ten
(10) days after resolution of the matter by the Special Master: (i) all fees and costs incurred by Cambrex in submitting that part of Cambrex's objection that was resolved in Cambrex's favor by the Special Master, including but not limited to all consultant's and attorneys' fees and the reasonable hourly fee for employee time used to address such objection or challenge; and (ii) all fees and costs of the Special Master associated with addressing and adjudicating that part of Cambrex's objection or challenge that was resolved in Cambrex's favor.

1.5 Certifications. All Certificates to be delivered under this Article I shall be delivered simultaneously to the Escrow Agent and the other party to this Environmental Escrow Agreement.

1.6 Termination. This Environmental Escrow Agreement shall terminate upon the earlier of (a) the distribution of all of the Escrow Account in accordance with the terms hereof, (b) the date that is ten years from the date of the execution of this Agreement or (c) such earlier date on which the Escrow Agent receives a written assurance of concurrence (a "Completion Notice") by the jurisdictional Governmental or Regulatory Authorities (such as a "no further action" letter or its equivalent or acceptance by such Governmental or Regulatory Authority of Rutherford's final notice of completion) that Remediation at the Nepera Facility required under the RCRA RFI corrective action process has been completed as required by applicable law or, in

22

the event monitoring or maintenance of the Nepera Facility is required after completion of any Remediation, such monitoring and/or maintenance (exclusive of any pump-and-treat remedy involving groundwater) having been conducted for a period of at least two years without the imposition of additional remediation requirements, provided, however, that a Completion Notice will not terminate the Environmental Escrow Agreement if within twenty (20) days following Cambrex's receipt of a copy of the Completion Notice, Cambrex provides written notice to the Escrow Agent, with a copy to Rutherford, of its objection to the Completion Notice under Section 1.4.2 hereof (the "Completion Objection"); and provided further that subsequent to the Escrow Agent's receipt of a Completion Objection, this Environmental Escrow Agreement shall terminate if the Escrow Agent receives either (x) a joint notice from Rutherford and Cambrex stating that Rutherford and Cambrex have agreed that this Environmental Escrow Agreement shall be terminated, or (y) a copy of a final, non-appealable judgment of an arbitrator stating that the Completion Notice satisfies the requirements of Section 1.4.2 hereof. In the event that this Environmental Escrow Agreement terminates pursuant to Subsection (b) or (c) of this Section 1.6, the Escrow Agent shall deliver the amount of the Escrow Account then remaining (less any Fees) to Rutherford. In any event, upon termination of this Environmental Escrow Agreement, any remaining balance in the Escrow Account shall be paid to Rutherford.

ARTICLE II
CONCERNING THE ESCROW AGENT AND THE SPECIAL MASTER

2.1 Concerning the Escrow Agent.

2.1.1 General. Cambrex and Rutherford acknowledge and agree that the Escrow Agent (a) shall not be responsible for any of the other agreements referred to herein but shall be obligated only for the performance of such duties of the Escrow Agent as are specifically set forth in this Environmental Escrow Agreement, (b) shall not be obligated to take any legal or other action hereunder which might in its judgment involve expense or liability unless it shall have been furnished with indemnity acceptable to it, (c) may rely on and shall be protected in acting or refraining from acting upon any written notice, instruction, instrument, statement, request or document furnished to it hereunder and believed by it to be genuine and to have been signed or presented by the proper person, and shall have no responsibility for determining the accuracy thereof, and (d) may, at its sole expense, consult counsel satisfactory to it and the advice or opinion of such counsel shall be full and complete authorization and protection in respect of any action taken, suffered or omitted by it hereunder in good faith and in accordance with the advice or opinion of such counsel.

2.1.2 Expenses of Escrow. The Escrow Agent shall be entitled to compensation for out-of-pocket expenses incurred in performing the duties and obligations imposed under this Environmental Escrow Agreement and an annual fee in the amount of two-thousand and five hundred dollars ($2,500) for the term of this Environmental Escrow Agreement. All expenses incurred, and fees paid, shall be paid from the Environmental Deposit. The Escrow Agent shall not be entitled to any other fee or compensation.

2.1.3 Waiver of Liens. Without prejudice to Section 1.6, 2.1.2, and any other provision of this Environmental Escrow Agreement specifically providing for the payment of amounts due to the Escrow Agent hereunder, the Escrow Agent hereby waives and agrees not to

23

assert any right of setoff or bank, statutory, equitable or other lien in respect of the Escrow Account or the distribution thereof.

2.1.4 Liability of the Escrow Agent. Upon disbursement of all of the Escrow Account in accordance with the terms hereof, the Escrow Agent shall be fully and finally released and discharged from any and all duties, obligations and liabilities hereunder. In the event of a dispute between any of the parties hereto as to their respective rights and interests hereunder, the Escrow Agent shall be entitled to hold the Escrow Account then in its possession hereunder until such dispute shall have been resolved by the parties in dispute and the Escrow Agent has been notified by instrument jointly signed by all of the parties in dispute, or until such dispute shall have been finally adjudicated as provided in Section 3.9. In the event of a dispute, the Escrow Agent may file an interpleader action and pay the Escrow Account into the registry of the court. Neither the Escrow Agent nor any of its directors, officers or employees shall be liable to anyone for any action taken or omitted to be taken by it or any of its directors, officers or employees hereunder except in the case of any loss, liability or expense primarily caused by the Escrow Agent's gross negligence, bad faith or willful misconduct. Cambrex and Rutherford shall, jointly and severally, indemnify the Escrow Agent and hold it harmless without limitation from and against any loss, liability or expense of any nature incurred by the Escrow Agent arising out of or in connection with this Environmental Escrow Agreement or with the administration of its duties hereunder, including, legal fees and expenses and other costs and expenses of defending or preparing to defend against any claim of liability, unless such loss, liability or expense is primarily caused by the Escrow Agent's gross negligence, bad faith or willful misconduct. In no event shall the Escrow Agent be liable for indirect, punitive, special or consequential losses or damages (including without limitation lost profits), even if advised of the possibility of such losses or damages and regardless of the form of action.

2.1.5 Resignation. The Escrow Agent may at any time resign as Escrow Agent hereunder by providing sixty (60) calendar days' prior written notice of resignation to the other parties hereto. Prior to the effective date of the resignation as specified in such notice, Cambrex and Rutherford shall issue to the Escrow Agent a written instruction authorizing redelivery of the Escrow Account to a successor escrow agent selected by Cambrex and Rutherford. If no successor escrow agent is named by Cambrex and Rutherford, the Escrow Agent may apply to a court of competent jurisdiction for the appointment of a successor escrow agent. The provisions of 2.1.4 above shall survive the resignation or removal of the Escrow Agent or the termination of this Environmental Escrow Agreement.

2.2 Concerning the Special Master.

2.2.1 "Special Master" shall mean an individual retained by the Parties to address and decide certain issues related to Qualified Expenses, as defined in Section 1.4.1 and further set forth in this Agreement. The Special Master shall have experience in the area of environmental Remediation and in submitting or reviewing invoices for remediation work.

2.2.2 The Special Master shall be jointly designated by the Parties within thirty (30) days after the execution of this Agreement. If the Parties are unable to agree on the identity of a Special Master, the Special Master shall be chosen by the Escrow Agent.

24

2.2.3 All expenses of the Special Master incurred in carrying out his or her responsibilities under this Agreement shall be paid by the Parties, as set forth in Paragraph 1.4.5 herein.

ARTICLE III
MISCELLANEOUS

3.1 Entire Agreement. This Environmental Escrow Agreement, including the Exhibits to this Environmental Escrow Agreement, constitutes the entire agreement of the parties to this Environmental Escrow Agreement with respect to the subject matter hereof and supersedes all prior agreements and undertakings, both written and oral, with respect to the subject matter hereof.

3.2 Notices. All notices, requests, claims, demands and other communications to any party hereunder must be in writing and must be given by hand delivery, by courier service or by facsimile to the applicable party at the following address:

if to Cambrex, to:

Cambrex Corporation

One Meadowlands Plaza
East Rutherford, New Jersey 07073 Attention: General Counsel

with a copy to:

Milbank, Tweed, Hadley & McCloy LLP One Chase Manhattan Plaza New York, New York 10005
Attention: Thomas A. Arena, Esq.

if to Rutherford, to:

Vertellus Specialties Inc.

300 North Meridian Street Suite 1500
Indianapolis, Indiana 46204 Attention: General Counsel

with a copy to:

Akin Gump Strauss Hauer & Feld LLP 1333 New Hampshire Avenue, NW Washington, DC 20036
Attention: Perry M. Rosen, Esq.

25

if to the Escrow Agent, to:

Wells Fargo Bank, National Association
300 North Meridian Street, 16th Floor
Indianapolis, Indiana 46204-1751

Attention: John Alexander, Corporate Trust & Escrow Services

or any other address or facsimile number as a party may hereafter specify by notice to the other parties to this Environmental Escrow Agreement in accordance with this Section 3.2. Delivery of each notice, request or other communication will be effective (a) if given by hand delivery or courier service, when delivered at the address specified in this Section 3.2, or (b) if given by facsimile transmission, when the facsimile is transmitted to the facsimile number specified in this Section 3.3 and the appropriate confirmation is received.

3.3 Disbursements. All disbursements to Rutherford or Cambrex pursuant to this Environmental Escrow Agreement shall be made via wire transfer of immediately available funds to the following account:

(i) if to Rutherford, to the following account:

Bank: National City Bank
Location: Indianapolis, Indiana
Account Number: 984-987-847 ABA Number: 074-000-065
Reference: Rutherford Chemicals LLC HOP# 130 Attention: David Schwind

or such other account as such party may hereafter specify to by notice to the Escrow Agent;

(ii) if to Cambrex, to the following account:

Bank: Bank of New York
Location: One Wall Street, New York, New York 10286 Account Number: 6106823683 ABA Number: 021000018
Reference: Rutherford Escrow Attention: Gregory Sargen

or such other account as such party may hereafter specify to by notice to the Escrow Agent;

3.4 Amendments and Waivers.

3.4.1 Writing Required. Any provision of this Environmental Escrow Agreement may be amended or waived if, and only if, such amendment or waiver is in writing and signed, in the case of an amendment, by Cambrex, Rutherford and the Escrow Agent or, in the case of a waiver, by the party against whom the waiver is to be effective.

26

3.4.2 No Implied Waiver. No failure or delay by any party hereto in exercising any right, power or privilege hereunder will operate as a waiver thereof nor will any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.

3.5 Successors and Assigns. The provisions of this Environmental Escrow Agreement shall be binding upon and inure to the benefit of the parties to this Environmental Escrow Agreement and their respective successors and assigns. Rutherford may transfer or assign in whole or in part its rights and obligations under this Environmental Escrow Agreement to (i) one or more of its subsidiaries or affiliates; (ii) any financial institution providing purchase money or other financing to Rutherford or to one or more of its subsidiaries or affiliates; or
(iii) a purchaser of Rutherford or any portion thereof or a purchaser of any of the Rutherford Facilities, or a substantial portion of any one of the Rutherford Facilities, but no such transfer or assignment will relieve Rutherford of any of its obligations hereunder. No assignment of interests of any of the other Parties hereto shall be binding upon the Escrow Agent unless and until written notice of such assignment is provided to and acknowledged by the Escrow Agent.

3.6 Benefit; No Joint Venture. Notwithstanding anything to the contrary contained in this Environmental Escrow Agreement, nothing in this Environmental Escrow Agreement, expressed or implied, is intended to confer on any person or entity other than the parties to this Environmental Escrow Agreement or their respective successors and assigns, any rights, remedies, obligations or liabilities under or by reason of this Environmental Escrow Agreement. Neither this Environmental Escrow Agreement nor anything contained herein shall create or be deemed to create a partnership, joint venture or other joint or equity type agreement between Rutherford and Cambrex.

3.7 Tax Issues. The parties acknowledge that the Escrow Agent does not have any interest in the Escrow Deposit, but is serving only as escrow holder hereunder. Without limiting the foregoing, but subject to the other provisions of this Agreement, Rutherford shall be responsible for determining if there are any taxes relating to the Escrow Deposit, the Escrow Account, all property or funds on deposit therein and all dividends, distributions, interest, income and earnings thereon. If it is determined that any such taxes are due and owing, they may be disbursed to Rutherford from the Escrow Account upon a written direction to the Escrow Agent from Rutherford.

3.8 Certain Interpretive Matters.

3.8.1 Certain References. Unless the context otherwise requires, all references in this Environmental Escrow Agreement to Sections or Exhibits are to Sections or Exhibits of or to this Environmental Escrow Agreement. All references to "$" or dollar amounts are to lawful currency of the United States of America.

3.8.2 Titles and Headings. Titles and headings to Sections and Exhibits in this Environmental Escrow Agreement are inserted for convenience of reference only, and are not intended to be a part of or to affect the meaning or interpretation of this Environmental Escrow Agreement.

27

3.8.3 Governing Law. This Environmental Escrow Agreement shall be construed in accordance with and governed by the internal substantive law of the State of New York regardless of the laws that might otherwise govern under principles of conflict of laws applicable thereto.

3.9 Consent to Jurisdiction; Arbitration. Any disputes arising from or relating to this Environmental Escrow Agreement shall be submitted to and resolved by binding arbitration conducted in the State of New York, County of New York, in accordance with the Section 4.1 of the Settlement Agreement. Judgment on any arbitration award may be entered in any court having jurisdiction.

3.10 Severability. If any provision of this Environmental Escrow Agreement is determined by a Governmental or Regulatory Authority to be invalid, void or unenforceable, the remainder of the provisions of this Environmental Escrow Agreement will remain in full force and effect and will in no way be affected, impaired or invalidated.

3.11 Counterparts; Effectiveness. This Environmental Escrow Agreement may be executed in any number of counterparts, each of which will be an original, with the same effect as if the signatures thereto were upon the same instrument. This Environmental Escrow Agreement will become effective when both of the following events occur: (a) each party to this Environmental Escrow Agreement receives counterparts hereof signed by the other parties to this Environmental Escrow Agreement; and (b) each party to this Environmental Escrow Agreement receives counterparts signed by the other parties to the Settlement Agreement.

IN WITNESS WHEREOF, the parties to this Environmental Escrow Agreement have caused this Environmental Escrow Agreement to be duly executed by their respective authorized officers as of the day and year first above written.

CAMBREX:

CAMBREX CORPORATION

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

NEPERA, INC., CASCHEM, INC.,
ZEELAND CHEMICALS, INC., NEPCAM, INC.

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

28

CAMBREX LIMITED

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

RUTHERFORD:

RUTHERFORD CHEMICALS LLC.,
VERTELLUS SPECIALTIES HOLDINGS CORP.

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

VERTELLUS SPECIALTIES UK LTD.,
VERTELLUS SPECIALTIES HOLDINGS UK LTD.

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

ESCROW AGENT:

WELLS FARGO BANK, NATIONAL ASSOCIATION,
as escrow agent

By: /s/
    ------------------------------------
Name:
      ----------------------------------
Title:
       ---------------------------------

29

EXHIBIT A

SETTLEMENT AGREEMENT

P. 30

EXHIBIT B

RUTHERFORD'S CERTIFICATE OF INSTRUCTION

Pursuant to Section 1.4.4 of the Environmental Escrow Agreement, dated as of July 30, 2007 (the "Environmental Escrow Agreement"), by and between Rutherford Chemicals LLC, Vertellus Specialties Holdings UK Ltd (formerly Rutherford Chemicals UK Ltd.), Vertellus Specialties UK Ltd. (formerly Seal Sands Chemicals Ltd.), and Vertellus Specialties Holdings Corp. (formerly Rutherford Chemicals Holdings Corp.) (collectively, "Rutherford"), and Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland, Inc., Nepcam, Inc., and Cambrex Ltd. (collectively, "Cambrex") and Wells Fargo National Bank, National Association, as escrow agent (the "Escrow Agent"), Rutherford hereby certifies to the Escrow Agent and Cambrex that (i) the attached receipts or invoices are for costs incurred by Rutherford which are Qualified Expenses and (ii) Rutherford has not previously received funds from the Escrow Account in respect of such expenses.

The Escrow Agent is hereby instructed to release to Rutherford, on the date that is no earlier than sixteen (16) calendar days and no later than twenty-three (23) days after the receipt of this Certificate by the Escrow Agent, an aggregate amount of $__________ from the Escrow Account in respect of such Qualified Expenses. If the Escrow Agent receives an Objection to this Certification from Cambrex within fifteen (15) calendar days after the receipt of this Certificate by the Escrow Agent, the Escrow Agent is hereby instructed to release to Rutherford an amount of the Escrow Account equal to the aggregate amount of such expenses not disputed by such Objection and retain the disputed amount in accordance with Section 1.4.5 of the Environmental Escrow Agreement.

All terms beginning with initial capital letters not otherwise defined in this Certificate have the same meaning as set forth in the Environmental Escrow Agreement.

Dated:                                  RUTHERFORD:
       ------------------------------
                                        RUTHERFORD CHEMICALS LLC.,
                                        VERTELLUS SPECIALTIES HOLDINGS CORP.


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------


                                        VERTELLUS SPECIALTIES UK LTD.,
                                        VERTELLUS SPECIALTIES HOLDINGS UK LTD.


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

P. 31

EXHIBIT C

CAMBREX'S OBJECTION CERTIFICATE

Pursuant to Section 1.4.5 of the Environmental Escrow Agreement, dated as of July 30, 2007 (the "Environmental Escrow Agreement"), by and between Rutherford Chemicals LLC, Vertellus Specialties Holdings UK Ltd (formerly Rutherford Chemicals UK Ltd.), Vertellus Specialties UK Ltd. (formerly Seal Sands Chemicals Ltd.), and Vertellus Specialties Holdings Corp. (formerly Rutherford Chemicals Holdings Corp.) (collectively, "Rutherford"), and Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland, Inc., Nepcam, Inc., and Cambrex Ltd. (collectively, "Cambrex") and Wells Fargo National Bank, National Association, as escrow agent (the "Escrow Agent"), Cambrex hereby:

(a) disputes that $_______ of the Owed Amount referred to in the Certificate of Instruction dated _________, ____ is for Qualified Expenses and is payable to Rutherford by reason thereof;

(b) certifies that a copy of this Objection Certificate has been served upon Rutherford;

(c) objects to your making payment to Rutherford in the amount of $_______ as provided in such Certificate of Instruction; and

[(d) does not object to your making payment to Rutherford in the amount of $________ as provided in such Certificate of Instruction.]

All terms beginning with initial capital letters not otherwise defined in this Certificate have the same meaning as set forth in the Environmental Escrow Agreement.

Dated:                                  CAMBREX:
       ------------------------------
                                        CAMBREX CORPORATION


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------


                                        NEPERA, INC., CASCHEM, INC.,
                                        ZEELAND, CHEMICALS, INC., NEPCAM, INC.


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

P. 32

CAMBREX LIMITED

By:

Name:
Title:

P. 33

EXHIBIT D

RESOLUTION CERTIFICATE

Pursuant to Section 1.4.5 of the Environmental Escrow Agreement, dated as of July 30, 2007 (the "Environmental Escrow Agreement"), by and between Rutherford Chemicals LLC, Vertellus Specialties Holdings UK Ltd (formerly Rutherford Chemicals UK Ltd.), Vertellus Specialties UK Ltd. (formerly Seal Sands Chemicals Ltd.), and Vertellus Specialties Holdings Corp. (formerly Rutherford Chemicals Holdings Corp.) (collectively, "Rutherford"), and Cambrex Corporation, Nepera, Inc., CasChem Inc., Zeeland, Inc., Nepcam, Inc., and Cambrex Ltd. (collectively, "Cambrex") and Wells Fargo National Bank, National Association, as escrow agent (the "Escrow Agent"), Rutherford and Cambrex hereby:

(a) certify that (i) Rutherford and Cambrex have resolved their dispute as to the matter described in the Certificate of Instruction dated __________, 20__ and the related Objection Certificate dated ___________, 20__ and (ii) the final Owed Amount with respect to the matter described in such Certificates is $______________; and

(b) agree that the Owed Amount designated in such Certificate of Instruction, to the extent, if any, it exceeds the Owed Amount referred to in clause (ii) of paragraph (a) above, shall be deemed not payable to Rutherford and such Certificate of Instruction is hereby cancelled.

All terms beginning with initial capital letters not otherwise defined in this Certificate have the same meaning as set forth in the Environmental Escrow Agreement.

Dated:                                  RUTHERFORD:
       ------------------------------
                                        RUTHERFORD CHEMICALS LLC.,
                                        VERTELLUS SPECIALTIES HOLDINGS CORP.


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------


                                        VERTELLUS SPECIALTIES UK LTD.,
                                        VERTELLUS SPECIALTIES HOLDINGS UK LTD.


                                        By:
                                            ------------------------------------
                                        Name:
                                              ----------------------------------
                                        Title:
                                               ---------------------------------

P. 34

CAMBREX:

CAMBREX CORPORATION

By:

Name:
Title:

NEPERA, INC., CASCHEM, INC.,
ZEELAND CHEMICALS, INC., NEPCAM, INC.

By:

Name:
Title:

CAMBREX LIMITED

By:

Name:
Title:

P. 35

EXHIBIT E

TAX REPORTING

Pursuant to and in accordance with Section 3.7 of the Environmental Escrow Agreement, dated as of July 30, 2007 (the "Environmental Escrow Agreement"), the Escrow Agent shall report the income earned, if any, in the Escrow Account, to the following entity:

Vertellus Specialties Inc. 300 North Meridian Street, Suite 1500 Indianapolis, Indiana 46204 Attention: General Counsel

Fed. I.D. No. 35-0607240

P. 36

EXHIBIT 31.1

CAMBREX CORPORATION

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

I, James A. Mack, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cambrex Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; and

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

                                     /s/ James A. Mack
                                     ------------------------------------
                                     James A. Mack
                                     Chairman of the Board of Directors,
                                     President and Chief Executive Officer

Dated: August 7, 2007

32

EXHIBIT 31.2

CAMBREX CORPORATION

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

I, Gregory P. Sargen, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Cambrex Corporation;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15 (f) and 15d-15 (f)) for the registrant and have:

a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared; and

b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; and

c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

                                     /s/ Gregory P. Sargen
                                     ------------------------------------------
                                     Gregory P. Sargen
                                     Vice President and Chief Financial Officer

Dated: August 7, 2007

33

EXHIBIT 32.1

CAMBREX CORPORATION

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Cambrex Corporation (the "Company") on form 10-Q for the period ending June 30, 2007, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, James A. Mack, Chairman of the Board of Directors, President and Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that:

1. The Report fully complies with the requirements of Section 13 (a) or
15 (d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:   August 7, 2007

                                     /s/ James A. Mack
                                     --------------------------------------
                                     James A. Mack
                                     Chairman of the Board of Directors,
                                     President and Chief Executive Officer

34

EXHIBIT 32.2

CAMBREX CORPORATION

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(18 U.S.C. SECTION 1350)

In connection with the Quarterly Report of Cambrex Corporation (the "Company") on form 10-Q for the period ending June 30, 2007, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gregory P. Sargen, Vice President and Chief Financial Officer of the Company, certify, pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350), that:

1. The Report fully complies with the requirements of Section 13 (a) or
15 (d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated:   August 7, 2007

                                     /s/ Gregory P. Sargen
                                     ------------------------------------------
                                     Gregory P. Sargen
                                     Vice President and Chief Financial Officer

35